Revue comparative des thérapeutiques hypolipémiantes

Voies biologiques, dynamique de l'efficacité, mécanismes cellulaires de la toxicité musculaire, pharmacogénomique et phénomène nocebo

Résumé

athéromateux maladie cardiovasculaireLes maladies cardiovasculaires sont un terme générique qui désigne les problèmes liés au cœur et aux vaisseaux sanguins, notamment les crises cardiaques, les accidents vasculaires cérébraux et le blocage des artères des jambes. reste la principale cause de décès dans le monde, et l'abaissement du taux de basse densité lipoprotéineUne lipoprotéine est un tout petit paquet qui transporte les graisses et le cholestérol dans votre circulation sanguine. Comme la graisse ne se dissout pas dans l'eau, elle a besoin d'une enveloppe protéique pour voyager. cholestérolLe cholestérol est une substance cireuse dont votre corps a besoin. Il entre dans la composition des parois cellulaires, des hormones, de la vitamine D et de la bile qui digère vos aliments. Vous en mettriez sans lui. (LDL-C) est le moyen pharmacologique le plus solidement validé pour réduire ce risque. L'arsenal thérapeutique s'est élargi des inhibiteurs de la 3-hydroxy-3-méthylglutaryl-coenzyme A (HMG-CoA) réductase aux inhibiteurs de l'ATP-citrate lyase, du Niemann-Pick C1-Like 1, proprotéine convertaseProprotein convertases are enzymes that activate other proteins by cutting them. PCSK9 belongs to this family — its full name is proprotein convertase subtilisin/kexin type 9. subtilisine/kexine de type 9 (PCSK9Le PCSK9 est une protéine produite par votre foie qui détruit les points d'amarrage que votre foie utilise pour éliminer le cholestérol de votre sang.), et angiopoïétine-like protéineLes protéines sont le nutriment que votre corps utilise pour développer et réparer les muscles et les tissus. 3, avec ester de cholestérolCholesteryl esters are storage forms of cholesterol in which a fatty acid is attached to cholesterol; they accumulate in large quantities inside foam cells and the extracellular spaces of plaques, and their depletion—measured as regression of the lipid-rich pool—is a primary marker of plaque improvement in primate regression studies. inhibiteurs de la protéine de transfert, voie orale Inhibiteurs de PCSK9Un inhibiteur de la PCSK9 est un médicament qui bloque cette protéine destructrice de cholestérol, laissant plus de sites de liaison disponibles pour éliminer les particules du sang., et les thérapies à base d'acides nucléiques ciblant la lipoprotéine(a) en développement avancé. Malgré un bénéfice cardiovasculaire non équivoque, la persistance thérapeutique est compromise par les effets indésirables signalés, principalement symptômes musculaires associés aux statines (SMAS)Statin-associated muscle symptoms is the clinical umbrella term for the spectrum of muscle-related complaints — pain, weakness, cramps, and fatigue — reported by patients taking statins, ranging from mild discomfort driven largely by the nocebo effect to rare serious myopathy..

Cette revue synthétise la pharmacologie moléculaire, l'efficacité comparative et le profil de sécurité musculaire de toutes les classes de médicaments hypocholestérolémiants actuellement disponibles. Elle aborde les effets musculaires au sens large plutôt que sous le seul angle des courbatures, en traitant de la fatigue, de la baisse d'énergie et capacité d'exerciceExercise capacity is a quantitative measure of the maximum physical work a person can perform, typically assessed during a graded stress test as peak workload in watts, peak oxygen consumption (VO2 max), or metabolic equivalents (METs). In the article, a decline in exercise capacity four months after stenting indicated that the procedure alone had not resolved the underlying disease. comme des résultats dotés de leur propre base factuelle distincte. Elle distingue quatre entités biologiquement distinctes qui sont fréquemment confondues : (i) les symptômes médiés par l'effet nocebo, qui représentent la grande majorité des plaintes musculaires attribuées à statinesUne statine ralentit l'enzyme que votre foie utilise pour fabriquer le cholesterol. Votre foie réagit en extrayant plus de cholesterol de votre sang, ce qui est la veritable source de bienfaits. — d’après les données individuelles des participants issues de l’étude ’ Cholesterol Treatment Trialists », plus de 90% des cas de symptômes musculaires signalés chez les participants ayant reçu des statines n’étaient pas imputables au médicament ; (ii) une véritable myalgie d’origine pharmacologique, touchant une minorité restreinte mais bien réelle ; (iii) une véritable myopathie et rhabdomyolyseRhabdomyolysis is the rapid breakdown of skeletal muscle tissue that releases cellular contents — including myoglobin — into the bloodstream; a key warning sign is dark tea- or cola-colored urine, and if untreated it can cause acute kidney failure., qui sont rares et dépendent de la dose ; et (iv) myopathie nécrosante à médiation immunitaire anti-HMGCRAnti-HMGCR immune-mediated necrotizing myopathy is a rare autoimmune muscle disease, affecting roughly 2 per 100,000 statin users per year, in which the body generates antibodies against HMG-CoA reductase; unlike ordinary statin myalgia, it persists and worsens after the drug is stopped and requires immunosuppressive treatment., une maladie auto-immune rare qui persiste après l'arrêt du médicament et nécessite une immunosuppression plutôt que des rassurances. Données probantes provenant des données de participants individuels de la Cholesterol Treatment Trialists’ Collaboration méta-analyseUne méta-analyse combine statistiquement les résultats de nombreuses études distinctes en une seule estimation globale., le SAMSONSAMSON was an unusual trial in which patients who had quit statins because of side effects took, in random order, the statin, an identical placebo, and no pill at all. et StatinWISEStatinWISE was an n-of-1 randomized trial in which individual patients alternated between statin tablets and placebo tablets across multiple periods, allowing a within-person comparison of symptoms; its results confirmed that a substantial portion of muscle symptoms attributed to statins are not pharmacologically caused. essais n-de-1A blinded, randomized crossover trial conducted in a single individual who alternates between active treatment and placebo in multiple cycles, allowing attribution of symptoms to drug versus expectation within that person rather than relying on population averages., la comparaison en aveugle par rapport à l'étude en ouvert ASCOT-LLA, et le test de réexposition randomisé GAUSS-3 sont intégrés à des conseils pharmacogénomiques et à un algorithme de prise en charge pratique. Le message clinique central est double : les cliniciens ne doivent ni accepter les symptômes musculaires rapportés comme la preuve d'une toxicité pharmacologique, ni les rejeter comme étant invariablement d'ordre psychologique.

1. Introduction

Les maladies cardiovasculaires induites par l'athérosclérose (ACV) restent la principale cause de mortalité dans le monde1La relation entre le LDL-C et le risque athérogène est causale, dose-dépendante et cumulative dans le temps, et le bénéfice clinique de la réduction du LDL-C est proportionnel à l'amplitude absolue de la réduction obtenue et à sa durée, indépendamment, pour l'essentiel, du mécanisme par lequel elle est obtenue.

Pourtant, la traduction de ces données probantes en bénéfice au niveau de la population est limitée moins par l'efficacité que par la persistance. Une fraction substantielle des patients à qui l'on prescrit des statines les arrêtent dans les deux ans, invoquant le plus souvent des symptômes musculaires. L'écart qui en résulte entre l'efficacité démontrée dans les essais et le bénéfice réalisé dans la pratique est l'une des pertes évitables les plus importantes en cardiologie préventive.

La résolution de ce problème exige de la précision quant à ce qui est réellement observé lorsqu'un patient signale des douleurs musculaires sous statine. Les données actuelles permettent cette précision. Cette revue a par conséquent trois objectifs : décrire la pharmacologie moléculaire et l'efficacité comparative de tous les hypolipidémiants disponibles ; définir la base biologique de la toxicité musculaire et les raisons pour lesquelles certains agents épargnent entièrement le squelette musculaire ; et quantifier la part de la charge des symptômes musculaires signalés qui est attribuable au médicament plutôt qu'à l'attente, au vieillissement ou à la coïncidence.

1.1 Note sur la terminologie et le champ d'application

Cet article est un revue narrativeUne revue narrative est un type d'article scientifique qui synthétise la recherche existante sur un sujet par la sélection et l'interprétation d'experts plutôt que par une recherche exhaustive préenregistrée avec une notation formelle des biais ; contrairement à une revue systématique ou à une méta-analyse, ses conclusions peuvent refléter le jugement éditorial des auteurs quant au choix des études à privilégier. avec une synthèse quantitative des données d'essais publiées. Il ne s'agit pas d'une méta-analyse de novo : aucune estimation d'effet poolée n'a été calculée par les auteurs, et tous les chiffres poolés cités sont ceux rapportés par les investigateurs originaux ou par des méta-analyses publiées, qui sont identifiées comme telles. Lorsque les estimations divergent entre les sources, le conflit est mentionné plutôt que résolu par préférence.

2. Voies biologiques et mécanismes d'action moléculaires

Thérapeutique hypolipémiantBaisser les lipides signifie réduire les particules nocives porteuses d'ApoB dans votre sang — par l'alimentation, les médicaments ou les deux. est obtenu en perturbant hépatique synthèse du cholestérolCholesterol synthesis is your body making its own cholesterol, mostly in the liver. Almost every cell can do it., l'absorption intestinale du cholestérol, hépatique Recyclage du récepteur des LDL (LDLR)The process by which LDL receptors on liver cell surfaces bind and internalize ApoB-containing lipoprotein particles, then return to the cell surface to capture more particles; PCSK9 normally tags these receptors for destruction after endocytosis, and blocking PCSK9 allows receptors to recycle repeatedly, dramatically increasing LDL clearance., ou le catabolisme des lipoprotéines. Ces différences pharmacodynamiques déterminent non seulement la puissance mais aussi la distribution tissulaire, et par conséquent le profil des effets indésirables. La distinction qui importe le plus pour la sécurité musculaire est simple : le médicament pénètre-t-il dans les myocytes squelettiques et, si c'est le cas, interfère-t-il avec une voie métabolique dont le muscle a besoin ?

Figure 1. Cibles moléculaires des classes de médicaments hypolipémiants. Les statines et acide bempédoïqueBempedoic acid is a cholesterol-lowering pill that works in the liver, at a point just before where statins act. agir sur deux nœuds distincts de l'hépatique voie du mévalonateThe mevalonate pathway is the multi-step biochemical route by which cells, primarily in the liver, synthesize cholesterol and related molecules; statins and bempedoic acid act at two separate nodes of this pathway to reduce cholesterol production.; ézétimibeL'ézétimibe est un comprimé qui empêche vos intestins d'absorber le cholestérol. agit au niveau de la bordure en brosse des entérocytes ; les agents ciblant le PCSK9 agissent dans la circulation ou au sein de l'hépatocyte pour préserver Récepteur des LDLLe récepteur des LDL est un point d'amarrage sur les cellules hépatiques qui capture les particules de LDL dans le sang et les attire pour les décomposer. recyclage. EvinacumabL'évinacumab est un anticorps injectable qui bloque l'ANGPTL3, utilisé pour les formes héréditaires de cholestérol les plus graves. est le seul agent dont l'effet ne dépend pas de LDLLe LDL, ou lipoprotéine de basse densité, est la principale particule qui transporte le cholesterol dans votre sang, et la principale qui se coince dans les parois artérielles. densité des récepteurs, c'est pourquoi il conserve son activité dans les récepteurs nuls hypercholestérolémie familiale homozygoteL'hypercholestérolémie familiale homozygote, ou HoFH, est la forme rare et grave d'hypercholestérolémie héréditaire, où un enfant hérite du gène défectueux de ses deux parents au lieu d'un seul..

2.1 Inhibiteurs de la HMG-CoA réductase (Statines)

Les statines inhibent de manière compétitive HMG-CoA réductaseHMG-CoA reductase is the rate-limiting enzyme in the liver's cholesterol biosynthetic (mevalonate) pathway; statins work by competitively blocking it, reducing the liver's own cholesterol production and prompting it to pull more LDL out of the bloodstream., l'enzyme limitante convertissant le HMG-CoA en mévalonate dans la voie de biosynthèse du cholestérol. L'épuisement du stock intra-hépatique stérolA sterol is a family of waxy molecules built on the same four-ring structure. Cholesterol is the one animals make; plants make their own versions. pool active la protéine de liaison à l'élément régulateur des stérols 2 (SREBP-2SREBP-2 (sterol regulatory element-binding protein 2) is a transcription factor that senses low intracellular sterol levels in the liver and responds by increasing the production and surface expression of LDL receptors, thereby accelerating clearance of LDL from the blood.), ce qui augmente la transcription et l'expression à la surface de LDLRLDLR est le gène qui code pour le récepteur des LDL, le point d'amarrage que votre foie utilise pour extraire les particules de cholestérol de la circulation. sur les membranes des hépatocytes, accélérant la clairance des LDL et des lipoprotéines de très basse densité circulantes (VLDLLes VLDL, ou lipoprotéines de très basse densité, sont les particules fabriquées par votre foie pour acheminer les triglycérides vers le reste du corps.) particules résiduelles.

Toutes les statines ont un effet hépatosélectif, principalement en raison d'une capture hépatique efficace au premier passage. Elles diffèrent cependant dans la manière dont cette capture est réalisée et dans la facilité avec laquelle elles atteignent les tissus extra-hépatiques :

• Statines lipophiles (atorvastatineL'atorvastatine, vendue sous le nom de Lipitor, est l'une des deux statines les plus puissantes et l'un des médicaments les plus prescrits au monde., simvastatine, lovastatine, fluvastatine, pitavastatineA statin notable for being highly potent per milligram, lowering LDL-C approximately 33–55% across its dose range of 1–16 mg/day and outperforming pravastatin at equivalent milligram doses in head-to-head studies., et le cérivastatine retiré du marché) : possèdent une perméabilité membranaire suffisante pour la diffusion passive à travers les membranes cellulaires, y compris celles des myocytes squelettiques. Ils sont par conséquent plus sensibles au métabolisme oxydatif par le système du cytochrome P450, à l'exception notable de la pitavastatine.
• Statines hydrophiles (rosuvastatineLa rosuvastatine, vendue sous le nom de Crestor, est la statine la plus puissante disponible et reste en grande partie dans le foie plutôt que de se propager dans le corps., pravastatineA moderate-intensity statin that lowers LDL-C roughly 22–32% across common licensed doses; because it is not metabolized through the CYP3A4 pathway and is hydrophilic, it is often preferred when muscle tolerability is a concern.): possèdent des domaines structurels polaires qui restreignent le passage membranaire passif. L'entrée hépatique dépend principalement du transport actif par le polypeptide transporteur d'anions organiques 1B1 (OATP1B1OATP1B1 is a hepatic uptake transporter encoded by the SLCO1B1 gene that actively carries statins — particularly hydrophilic ones — from the blood into liver cells; when its activity is reduced by genetic variants or drug interactions, statin plasma levels rise and muscle toxicity risk increases., encodé par SLCO1B1SLCO1B1 is the gene encoding the liver transporter OATP1B1, which carries hydrophilic statins — and to a lesser degree lipophilic ones — into hepatocytes; common variants in this gene reduce transporter activity, raising statin blood levels and increasing the risk of muscle toxicity.), et aucun des deux ne subit de métabolisme CYP450 substantiel.

Il importe d'énoncer d'emblée que cette distinction physico-chimique, bien que réelle et plausible sur le plan mécanistique, ne s'est pas traduite par une différence systématiquement démontrable dans les taux de symptômes musculaires cliniques. Cela est abordé directement à la section 6.4. La pitavastatine est l'illustration la plus claire de la raison pour laquelle l'heuristique simpliste selon laquelle lipophile équivaut à risqué échoue : c'est une molécule lipophile, mais comme elle ne subit pour ainsi dire aucun métabolisme par le CYP450, elle présente l'un des risques de myopathie liés aux interactions les plus faibles de toutes les statines.

2.2 La liste complète des statines

Sept statines sont actuellement commercialisées. Une huitième, la cérivastatine, a été retirée volontairement du marché mondial en 2001 en raison d'une incidence inacceptable de rhabdomyolyse fatale, en particulier lorsqu'elle était associée au gemfibrozil. Étant donné qu'une grande partie de l'anxiété historique entourant la myotoxicité des statines découle de l'expérience de la cérivastatine, elle est incluse ici pour donner du contexte.

Statine	Classe	Solubilité	Métabolisme principal	Notes de transport / interaction	Doses disponibles	Positionnement pratique
Atorvastatine	Synthétique	Lipophile	CYP3A4 (métabolites actifs)	Substrat de l'OATP1B1 ; les inhibiteurs du CYP3A4 augmentent l'exposition	10, 20, 40, 80 mg par jour	Agent de travail de force ; permis à longue demi-vie posologie un jour sur deuxA prescribing strategy in which a statin is taken every other day rather than daily, used clinically to reduce muscle symptoms in intolerant patients while preserving a meaningful portion of LDL-lowering effect, particularly with longer-half-life statins.
Rosuvastatine	Synthétique	Hydrophile	CYP minimal (traces de CYP2C9)	Substrat de l'OATP1B1 et de l'ABCG2 (BCRP) ; les variants de l'ABCG2 augmentent l'exposition	5, 10, 20, 40 mg par jour	Le plus puissant par mg ; longue demi-vie ; bon choix après une intolérance
Simvastatine	D'origine fongique	Lipophile	CYP3A4 (extensif)	Le plus fort SLCO1B1 signal de myopathie ; nombreuses limites de posologie avec des médicaments en interaction	5, 10, 20, 40 mg par jour (80 mg restreint)	Risque de myopathie le plus élevé induit par les interactions et le génotype parmi les statines commercialisées ; 80 mg non recommandé
Pravastatine	D'origine fongique	Hydrophile	Non-CYP (sulfatation)	Substrat d'OATP1B1 ; peu d'interactions avec les CYP	10, 20, 40, 80 mg par jour	Faible puissance mais profil d'interaction favorable ; utile en polypharmacie
Lovastatine	D'origine fongique	Lipophile	CYP3A4 (extensif)	ProdrogueA prodrug is a pharmacologically inactive compound that is converted into its active form by metabolic processes after administration; bempedoic acid is a prodrug activated specifically in the liver, which is why it avoids causing muscle side effects seen with statins. lactone ; plafonds de doses pour interactions multiples	10, 20, 40 mg (libération immédiate) ; 20–60 mg (libération prolongée)	Largement obsolète ; à prendre au repas du soir
Fluvastatine	Synthétique	Lipophile	CYP2C9 (principal)	Évite la voie du CYP3A4 ; les métaboliseurs lents du CYP2C9 accumulent le médicament	20, 40 mg ; 40 mg BID ; 80 mg XL	Utile lorsque l'interaction avec le CYP3A4 pose problème ; puissance la plus faible
Pitavastatine	Synthétique	Lipophile	CYP minimal ; glucuronidation	Non substrat du CYP3A4 ; ciclosporine contre-indiquée	1, 2, 4 mg par jour	Faible charge d'interaction ; couramment utilisé après l'intolérance à d'autres statines, sur des bases empiriques plutôt que par des essais comparatifs
Cérivastatine	Synthétique	Lipophile	CYP2C8 et CYP3A4	Retiré en 2001 ; rhabdomyolyse fatale, en particulier avec le gemfibrozil	Retiré	Historique uniquement ; source de beaucoup d'anxiété liée à la myotoxicité des statines

Tableau 1. Caractéristiques pharmacologiques de toutes les statines commercialisées ainsi que de la cérivastatine, retirée du marché. La classification de la solubilité suit Schachter (2005) [14]; les données de métabolisme et d'interaction suivent l'étiquetage du produit [15-21] et la directive CPIC 2022 [22]. IR = libération immédiate ; ER/XL = libération prolongée ; BID = deux fois par jour.

Classification de l'intensité des statines

Les schémas thérapeutiques de statines sont classés de manière conventionnelle en fonction de la réduction moyenne du LDL-C obtenue plutôt que par la seule dose. Les catégories d'intensité élevée, modérée et faible ont été définies dans les recommandations sur le cholestérol de l'ACC/AHA de 2013, qui ont introduit le tableau des intensités essentiellement dans sa forme actuelle [92], et ont été reportées dans les lignes directrices multisociétés AHA/ACC de 2018 [12]; elles restent d'usage général. La directive de 2018 elle-même a été remplacée : la directive 2026 ACC/AHA/Multisociety sur la prise en charge de DyslipidémieDyslipidemia is the medical word for an unhealthy pattern of fats in the blood. It can mean high LDL, high triglycerides, low HDL, or some combination., publié en mars 2026, l'abroge et le remplace [11], et les modifications du cadre qu'il introduit sont résumées à la section 9.3. La réduction du pourcentage de LDL-C reste une priorité affichée dans le document de 2026, de sorte que le tableau d'intensité ci-dessous conserve son utilité pratique, mais les lecteurs doivent noter qu'il s'inscrit désormais dans un cadre de prescription fondé sur des objectifs plutôt que purement sur l'intensité.

Haute intensité (réduction du LDL-C ≥ 50%)	Intensité modérée (réduction de 30 à 491 TP9T)	Faible intensité (réduction < 30%)
Atorvastatine 40–80 mg	Atorvastatine 10–20 mg	Simvastatine 10 mg
Rosuvastatine 20–40 mg	Rosuvastatine 5 à 10 mg	Pravastatine 10–20 mg
—	Simvastatine 20 à 40 mg	Lovastatine 20 mg
—	Pravastatine 40–80 mg	Fluvastatine 20–40 mg
—	Lovastatine 40–80 mg	Pitavastatine 1 mg
—	Fluvastatine 40 mg deux fois par jour ou 80 mg LP	—
—	Pitavastatine 2 à 4 mg	—

Tableau 2. Classification de l'intensité des statines, adaptée de la classification ACC/AHA introduite en 2013 [92] et reporté en 2018 [12Aucune dose de pravastatine, lovastatine, fluvastatine ou pitavastatine n'atteint la classification de haute intensité ; seuls l'atorvastatine et la rosuvastatine y parviennent. La ligne directrice sur la dyslipidémie de 2026 qui a remplacé le document de 2018 ajoute des objectifs absolus de LDL-C et de non-HDL-C en plus de la réduction en pourcentage ; voir la section 9.3.

2.3 Inhibiteurs de l'ATP-citrate lyase (acide bempédoïque)

L'acide bempédoïque est un promédicament synthétique à base d'acide dicarboxylique qui inhibe ATP-citrate lyase (ACLY)ATP-citrate lyase is an enzyme that acts two steps upstream of HMG-CoA reductase in the mevalonate pathway, cleaving citrate to supply the raw material for cholesterol synthesis; bempedoic acid inhibits this enzyme to reduce hepatic cholesterol production., une enzyme agissant deux étapes en amont de la HMG-CoA réductase dans la voie du mévalonate. L'ACLY clive le citrate d'origine mitochondriale en acétyl-CoA et en oxaloacétate, fournissant le substrat principal pour la synthèse de novo du cholestérol et des acides gras.

L'activité pharmacologique nécessite une estérification avec le coenzyme A pour former du bempédoyl-CoA, une réaction catalysée par l'acyl-CoA synthétase 1 à chaîne très longue (ACSVL1, codée par SLC27A2Dans la caractérisation originale de la molécule, l'ACSVL1 était fortement exprimée dans le foie, détectée de manière minime seulement dans le rein, et indétectable dans le muscle squelettique dans les conditions expérimentales étudiées ; de manière correspondante, le métabolite thioester actif a été récupéré dans le foie mais pas dans le muscle squelettique ni dans le tissu adipeux [24]. C'est la base mécanistique du profil d'épargne musculaire du médicament, et il s'agit d'un véritable argument de sélectivité tissulaire plutôt que pharmacocinétique.

L'acide bempédoïque active également la protéine kinase activée par l'AMP 5’ (AMPK) dans les systèmes précliniques, entraînant une régulation négative des enzymes lipogènes. Cela ne doit pas être présenté comme un mécanisme établi chez l'humain : l'examen intégré de la FDA note que l'activation de l'AMPK pourrait être spécifique aux rongeurs, que sa pertinence chez l'humain est incertaine et que la baisse du LDL-C peut se produire indépendamment de celle-ci [93]. Séparément, l'acide bempédoïque réduit la protéine C-réactive à haute sensibilité Protéine C-réactiveLa protéine C-réactive, ou CRP, est une substance produite par votre foie lorsqu'il y a une inflammation quelque part dans votre corps. Une version sensible du test, la hs-CRP, est utilisée pour évaluer le risque cardiaque. (hsCRP) d'environ 19 à 331 TP9T dans le cadre du programme CLEAR [25Au niveau rénal, l'acide bempédoïque et son métabolite l'acyl-glucuronide inhibent de manière compétitive le transporteur d'anions organiques 2 (OAT2) dans le tubule proximal. L'OAT2 assurant la sécrétion tubulaire de l'acide urique et de la créatinine, cette inhibition entraîne des élévations prévisibles et réversibles de l'urate et de la créatinine sériques, qui traduisent une compétition entre transporteurs plutôt qu'une atteinte parenchymateuse.

2.4 Inhibiteurs de Niemann-Pick C1-Like 1 (Ézétimibe)

L'ézétimibe se localise dans la bordure en brosse des entérocytes de l'intestin grêle et se lie au transporteur de stérols Niemann-Pick C1-Like 1 (NPC1L1NPC1L1 is the transporter in your intestine that absorbs cholesterol from food and bile. Ezetimibe blocks it.), bloquant l'endocytose biliaire et cholestérol alimentaireDietary cholesterol is the cholesterol in food — eggs, shrimp, liver, and other animal products. à travers l'épithélium intestinal sans affecter de manière significative l'absorption de triglycéridesLes triglycérides constituent la principale forme de graisse dans votre sang et dans les réserves de votre corps., acides biliairesBile acids are made by your liver from cholesterol and released into the gut to help digest fat., ou des vitamines liposolubles. Réduit chylomicronA chylomicron is a very large particle that carries fat from a meal out of your intestines and into your bloodstream. cholestérol résiduelRemnant cholesterol is the cholesterol carried in the leftovers of triglyceride-rich particles, after they have dropped off most of their fat. Son administration épuise les réserves intra-hépatiques de stérols et induit une augmentation de l'expression hépatique du récepteur LDL (LDLR). L’exposition systémique n’est pas négligeable : l’ézétimibe et son glucuronide actif sont facilement détectables dans le plasma, sont liés à plus de 90 % aux protéines, subissent une recirculation entéro-hépatique et ont une demi-vie d’environ 22 heures [27Ce qui importe pour la sécurité musculaire n'est pas l'absence de médicament en circulation, mais le fait que la cible pharmacologique soit intestinale et qu'aucune cible au niveau des muscles squelettiques n'ait été identifiée.

2.5 Thérapies ciblant PCSK9

PCSK9 est une protéine sécrétée sérine protéaseA class of enzymes that cleave protein bonds using a serine residue in their active site; PCSK9 belongs to this class and uses this activity to target LDL receptors for degradation. qui se lie au domaine extracellulaire du récepteur des LDL (LDLR) à la surface des hépatocytes et dirige le récepteur vers la dégradation lysosomale plutôt que vers le recyclage endosomal. Comme chaque molécule de LDLR peut autrement se recycler de nombreuses fois, empêcher sa dégradation augmente substantiellement la densité des récepteurs fonctionnels.

• Anticorps monoclonaux (évocumabL'évoculumab est un médicament injectable contre le cholestérol de la famille des inhibiteurs de la PCSK9, administré généralement toutes les deux à quatre semaines., alirocumabL'alirocumab, vendu sous le nom de Praluent, est un anticorps injectable qui bloque PCSK9, administré toutes les deux à quatre semaines.): anticorps IgG entièrement humains qui se lient au PCSK9 circulant libre avec une affinité élevée, bloquant stériquement l'interaction PCSK9-LDLR. Ils agissent principalement de manière extracellulaire, ce qui correspond au petit volume apparent de distribution rapporté pour l'évocumab, et n'ont pas de cible myocytaire intracellulaire identifiée ; l'étiquetage n'établit pas l'absence littérale de pénétration myocytaire [29,30].
• Petit ARN interférentinclisiranInclisiran is a cholesterol-lowering injection given just twice a year after the first two doses.): un ARNsi double brin synthétique conjugué à un ligand triantennaire de N-acétylgalactosamine (GalNAc). Le GalNAc se lie aux récepteurs de l'asialoglycoprotéine exprimés presque exclusivement sur les hépatocytes, ce qui entraîne une endocytose rapide médiée par récepteur. À l'intérieur de la cellule, l'ARNsi s'intègre dans le complexe d'interférence ARN (RISC) et dirige le clivage catalytique de l'ARN messager de la PCSK9, produisant une suppression prolongée qui permet une administration deux fois par an après la dose de charge31,34,35,59].
• Inhibiteurs peptidiques macrocycliques oraux (enlicitide) : peptides macrocycliques biodisponibles par voie orale qui se lient à PCSK9 avec une affinité de type anticorps, bloquant l'interaction PCSK9-LDLR par le même mécanisme que les anticorps monoclonaux mais administrés sous forme de comprimé. L'enlicitide (Lipfendra) a été approuvé par la FDA le 16 juillet 2026 en tant que premier inhibiteur oral de PCSK9, à la dose de 20 mg une fois par jour, et est abordé plus en détail dans la section 10.2 [36].

2.6 Inhibiteurs de l'angiopoïétine-like 3 (Evinacumab)

Evinacumab est un anticorps monoclonal entièrement humain dirigé contre ANGPTL3L'ANGPTL3 est une protéine qui ralentit la dégradation des particules riches en triglycérides dans le sang., un inhibiteur endogène de la lipase endotheliale et lipoprotéine lipaseLipoprotein lipase is an enzyme anchored to the walls of small blood vessels that strips triglycerides out of passing particles and hands the fat to muscle and fat tissue.. La neutralisation de l'ANGPTL3 désinhibe les deux lipases, accélérant la clairance des intermédiaires du métabolisme des VLDL et favorisant la dégradation intravasculaire directe des particules de lipoprotéines de densité intermédiaire et des LDL. De manière cruciale, cette voie ne nécessite pas de récepteurs LDLR fonctionnels, ce qui rend l'evinacumab efficace chez les homozygotes hypercholestérolémie familialeL'hypercholestérolémie familiale, ou HF, est une affection héréditaire dans laquelle le foie ne parvient pas à éliminer correctement le cholestérol du sang. Les taux sont très élevés dès la naissance. (HoFH), y compris les patients présentant des mutations nulles/nulles du gène LDLR qui répondent mal ou pas du tout aux statines et aux inhibiteurs de la PCSK9 [13,37Il est plus exact de décrire l'évinacumab comme étant largement plutôt que purement indépendant des LDLR. La démonstration de l'efficacité chez les patients null/null établit qu'il existe une voie indépendante des LDLR et qu'elle est suffisante en soi ; cela n'établit pas que la clairance médiée par les LDLR ne contribue en rien chez les patients qui conservent une fonction réceptrice partielle, et une certaine biologie résiduelle des récepteurs peut bien contribuer à la réponse dans ce groupe plus large43].

2.7 Inhibition de la protéine de transfert des esters de cholestérol (Obicetrapib, en phase de recherche)

CETPCETP is a protein that swaps cholesterol and triglycerides between HDL and the harmful ApoB particles. médiate le transfert des esters de cholestérol de HDLLe HDL, ou lipoprotéine de haute densité, est la particule souvent appelée " bon cholestérol ". Il récupère le cholestérol des tissus et le ramène vers le foie. à apolipoprotéineUne apolipoprotéine est une protéine attachée à une particule transporteuse de graisses dans votre sang. Les graisses et l'eau ne se mélangeant pas, ces protéines agissent comme une enveloppe qui permet aux graisses de voyager en toute sécurité dans la circulation sanguine. lipoprotéines contenant de l'apo B en échange de triglycérides. L'obicetrapib est un inhibiteur de la CETP oral, à faible dose et de nouvelle génération, qui réduit le C-LDL, l'apolipoprotéine B et lipoprotéine(a)La lipoprotéine(a), écrite Lp(a) et prononcée " L-P-petit-a ", est une particule de type LDL dotée d'une protéine supplémentaire très collante. while raising HDL-C. Earlier CETP inhibitorsA class of drugs designed to block cholesterol ester transfer protein, an enzyme that shuttles cholesterol from HDL to LDL particles; clinical trials such as ILLUMINATE and ACCELERATE showed that pharmacologically raising HDL-C this way did not reduce cardiovascular events, shifting the field's focus toward HDL function rather than concentration. failed for reasons of off-target toxicity (torcetrapib) or insufficient efficacy (dalcetrapib, evacetrapib), so the class carries appropriate historical caution pending cardiovascular outcome data [38].

3. Pharmacodynamic Efficacy Across Monotherapy and Combination Regimens

Statin monotherapy exhibits a non-linear relation dose-effetUne relation dose-effet signifie qu'une plus grande quantité de quelque chose produit un effet plus important, selon un gradient constant. curve governed by the so-called rule of six: each doubling of dose yields only about a 6% additional reduction in LDL-C. This attenuation occurs because intracellular sterol depletion triggers compensatory upregulation of intestinal cholesterol absorption via NPC1L1 and an increase in circulating PCSK9. The clinical implication is that dose escalation is an inefficient strategy compared with pathway combination.

3.1 Rational combination strategies

• Dual synthesis blockade (bempedoic acid plus statin): inhibiting the mevalonate pathway at two enzymatic nodes prevents upstream precursor accumulation and produces additive reductions in the intrahepatic sterol pool.
• Synthesis plus absorption blockade (statin or bempedoic acid plus ezetimibe): blunts the compensatory rise in intestinal cholesterol absorption induced by synthesis inhibition. This is the most cost-effective combination available.
• Synthesis plus clearance blockade (statin plus PCSK9 inhibitor): statines à haute intensitéUne statine à haute intensité est une dose censée réduire le LDL de 50 pour cent ou plus — en pratique, des doses plus élevées d'atorvastatine ou de rosuvastatine. upregulate LDLR but also raise circulating PCSK9. Adding a PCSK9 monoclonal antibody or inclisiran neutralizes this counter-regulatory rise, producing the largest reductions achievable with current therapy.

3.2 Comparative efficacy

The figures below are placebo-corrected or baseline-corrected LDL-C reductions from the principal registration trials. Two cautions apply. First, combination percentages are expressed relative to an untreated baseline and are therefore not additive with the monotherapy rows. Second, percentage reduction is a surrogate; only agents with completed cardiovascular outcome trials have demonstrated event reduction, and this is indicated explicitly in the final column.

Regimen	Standard dosing	Mean LDL-C reduction	Primary population	Outcome evidence
Low/moderate hydrophilic statin	Pravastatin 20–40 mg daily	20–35%	Prévention primaireLa prévention primaire consiste à traiter une personne qui n'a jamais eu de crise cardiaque ou d'accident vasculaire cérébral, afin d'empêcher qu'un premier événement ne se produise.; polypharmacy	Yes (WOSCOPS, LIPID, CARE)
High-intensity hydrophilic statin	Rosuvastatin 20–40 mg daily	45–55%	Elevated-risk primary prevention (the JupiterJUPITER tested a statin in people whose cholesterol was normal but whose CRP was elevated, suggesting hidden inflammation. population); also used at high ASCVD risk	Yes (JUPITER, a primary-prevention trial in apparently healthy adults)
Low/moderate lipophilic statin	Atorvastatin 10–20 mg daily	30–40%	Baseline dyslipidemia	Yes (ASCOT-LLA, CARDS)
High-intensity lipophilic statin	Atorvastatin 40–80 mg daily	50–60%	ACS; post-MI management	Yes (PROVE-IT, TNT)
NPC1L1 inhibitor monotherapy	Ezetimibe 10 mg daily	15–20%	Statin-intolerant adjunct	Adjunctive (IMPROVE-ITL'étude IMPROVE-IT a ajouté de l'ézétimibe à une statine après une crise cardiaque, testant si la réduction du LDL par un mécanisme autre qu'une statine serait bénéfique.)
Statin plus ezetimibe	High-intensity statin + ezetimibe 10 mg	≈ 60–65%	Advanced ASCVD failing statin alone	Yes (IMPROVE-IT)
ACL inhibitor monotherapy	Bempedoic acid 180 mg daily	≈ 18% on statin; ≈ 21–25% as monotherapy	Statin intolerance	Yes (Résultats CLEARCLEAR Outcomes was a large trial that tested bempedoic acid in people who couldn't tolerate statins, to see whether it lowered heart attack and stroke risk the way statins do., 2023)
ACL inhibitor plus ezetimibe	Bempedoic acid 180 mg + ezetimibe 10 mg	38–40%	Statin intolerance needing robust lowering	Component evidence
PCSK9 mAb monotherapy	Evolocumab 140 mg Q2W or 420 mg monthly	50–60%	Severe hypercholesterolemiaSevere hypercholesterolemia is defined by the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline as an LDL-C ≥190 mg/dL, non–HDL-C >220 mg/dL, and/or ApoB >140 mg/dL, representing a distinct management category in which maximally tolerated statin therapy is recommended as a Class 1 indication.; statin intolerance	LDL-C only in monotherapy use. FOURIERFOURIER a évalué l'évocumab, un inhibiteur de PCSK9, chez des patients présentant déjà une maladie cardiovasculaire et traités par des statines. et ODYSSEYODYSSEY OUTCOMES a évalué l'alirocumab chez des patients se remettant d'une crise cardiaque récente. OUTCOMES demonstrated event reduction with the antibody added to background statin or maximally tolerated statin therapy, not as monotherapy
PCSK9 mAb plus high-intensity statin	Evolocumab + atorvastatin 80 mg	≈ 70–80% from untreated baseline	Very high-risk ASCVD; HeFH	Yes (FOURIER)
PCSK9 siRNA	Inclisiran 284 mg day 0, month 3, then Q6M	48–52%	Adherence-limited patients	Pending (ORION-4, VICTORION-2P)
ANGPTL3 inhibitor	Evinacumab 15 mg/kg IV monthly	≈ 47–49%	Homozygous FH, including LDLR-null	Surrogate only
CETP inhibitor (investigational)	Obicetrapib 10 mg daily	≈ 33–37% added to background therapy	ASCVD/HeFH not at goal	Pending (PREVAIL)
Oral PCSK9 inhibitor	Enlicitide (Lipfendra) 20 mg once daily	≈ 56–59% placebo-adjusted at 24 weeks	HypercholesterolemiaL'hypercholestérolémie est un taux anormalement élevé de particules porteuses de cholestérol dans le sang, généralement provoqué chez les primates par la consommation d'un régime riche en cholestérol alimentaire et en graisses saturées, et associé à une formation accélérée de plaques dans la paroi des artères. including HeFH; oral alternative to injectables	LDL-C only; outcomes pending (CORALreef Outcomes)

Table 3. Comparative LDL-C lowering efficacy. Q2W = every two weeks; Q6M = every six months; ACS = syndrome coronarien aiguLe syndrome coronarien aigu (SCA) est le terme générique désignant toute diminution soudaine du flux sanguin vers le cœur — de l'angor instable à l'infarctus du myocarde caractérisé — causée par la rupture ou l'érosion soudaine d'une plaque d'athérome.; HeFH = heterozygous familial hypercholesterolemia. Obicetrapib remains investigational and is not approved for the use described. Enlicitide was approved in July 2026 on the basis of LDL-C lowering alone; its cardiovascular outcome trial is ongoing, so its row should be read as surrogate evidence despite the agent being marketed. Outcome trial sources for the final column: JUPITER [39]; IMPROVE-IT [28]; CLEAR Outcomes [40]; FOURIER [32]; ODYSSEY OUTCOMES [33]; le ORIONThe ORION trials tested inclisiran, the twice-yearly injection that silences PCSK9 production inside liver cells. program [34,35,59]; CORALreef [44-46]; BROADWAY [38]; evinacumab [13,43].

3.3 Evidence from Atherosclerosis Imaging

Percentage LDL-C reduction is a surrogate for a surrogate. Serial échographie intravasculaireL'échographie intravasculaire, ou IVUS, utilise une minuscule sonde ultrasonore introduite à l'intérieur d'une artère coronaire pour photographier la paroi de l'intérieur. (IVUS) provides an intermediate anatomical endpoint that links lipid lowering to the disease process itself, and the imaging trials are useful here for a specific reason: they demonstrate that régression de la plaqueLa régression de la plaque signifie que la plaque existante diminue réellement en taille, plutôt que de croître simplement plus lentement. tracks achieved LDL-C largely irrespective of the mechanism used to achieve it.

• SATURNESATURN a comparé directement les deux statines les plus puissantes à dose maximale, en mesurant la plaque coronaire par échographie intravasculaire. (NEJM 2011). 1,385 patients with coronary disease randomized to rosuvastatin 40 mg or atorvastatin 80 mg for 104 weeks. Percent atheroma volumeLe volume en pourcentage d'athérome, ou PAV, est la proportion d'un segment artériel occupée par la plaque plutôt que par la lumière libre. fell 0.99% with atorvastatin and 1.22% with rosuvastatin (P = 0.17, not significant); total athéromeL'athérome est un autre terme désignant le dépôt de graisse à l'intérieur de la paroi d'une artère — essentiellement un synonyme de plaque, utilisé plus souvent dans la littérature scientifique. volume fell more with rosuvastatin (−6.39 vs −4.42 mm³, P = 0.01). Regression occurred in the majority of patients in both arms (63.2% and 68.5%). Beyond its efficacy message, SATURN is a head-to-head comparison of a lipophilic and a hydrophilic statin at maximal dose and is referenced again in Section 6.4 [47].
• PRECISE-IVUS (JACC 2015). 246 Japanese patients with coronary disease randomized to atorvastatin alone or atorvastatin plus ezetimibe 10 mg, titrated to an LDL-C target below 70 mg/dL, with paired IVUS at 9–12 months in 202. Achieved LDL-C was 73.3 mg/dL on monotherapy versus 63.2 mg/dL on combination (P < 0.001), and the combination produced significantly greater regression of percent atheroma volume with comparable adverse event rates. This supports the principle that non-statin LDL lowering produces anatomical benefit and is not merely a laboratory effect [10].
• GLAGOVGLAGOV a ajouté un inhibiteur de PCSK9 à un traitement par statine et a mesuré la plaque coronaire par échographie intravasculaire avant et après. (JAMA 2016). 968 patients with angiographic coronary disease on statin therapy randomized to evolocumab 420 mg monthly or placeboUn placebo est un traitement factice — une pilule de sucre ou une injection de saline — administré afin que les chercheurs puissent déterminer ce qu'un vrai médicament fait réellement. for 76 weeks. LDL-C was 36.6 mg/dL on evolocumab versus 93.0 mg/dL on placebo. Percent atheroma volume fell by 1.01% relative to placebo (95% CI −1.38 to −0.64; P < 0.0001), and regression occurred in 64.3% versus 47.3% of patients. In an exploratory subgroup achieving a mean LDL-C of 24 mg/dL, 81.2% showed regression. GLAGOV is the principal evidence that benefit continues to accrue at LDL-C levels far below conventional targets, with no observed threshold below which further lowering ceased to help [9].

Two caveats apply. These are surrogate anatomical endpoints, not clinical events, and none of these trials was powered for outcomes. The populations were also selected — patients undergoing clinically indicated angiography rather than primary prevention cohorts. Their value lies in demonstrating biological coherence between LDL-C reduction and disease modification across three different drug mechanisms, not in establishing event reduction, which rests on the outcome trials cited in Table 3.

4. Cellular Mechanisms of Muscle Toxicity

Skeletal muscle toxicity from lipid-lowering therapy ranges from mild subjective discomfort to life-threatening muscle breakdown. Susceptibility is determined by whether the drug accumulates in myocytes and whether it perturbs a pathway on which muscle depends.

4.1 Proposed mechanisms of statin myotoxicity

Three mechanisms are proposed. They are presented here in descending order of evidential support, and it should be stated plainly that none has been definitively established as the cause of common myalgia in humans.

Isoprenoid depletion and impaired protein prenylation

Downstream of HMG-CoA reductase, the mevalonate pathway generates the non-sterol isoprenoids farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP). These are required for post-translational prenylation of small GTPases including Ras, Rho, and Rac. Loss of prenylation disrupts membrane anchoring, signal transduction, and cytoskeletal maintenance, and can trigger apoptosis in myocytes. This mechanism has the strongest experimental support, since supplementation with mevalonate or GGPP reverses statin-induced myotoxicity in cell culture, whereas cholesterol supplementation does not [48,49].

Mitochondrial dysfunction and coenzyme Q10 depletion

The mevalonate pathway also produces ubiquinone (coenzyme Q10), an electron carrier in the mitochondrial electron transport chain. Statins reduce circulating CoQ10, and it is hypothesized that intramyocellular depletion impairs complex I and complex IV activity, lowering ATP generation and increasing espèces réactives de l'oxygèneReactive oxygen species are unstable oxygen-containing molecules produced as a by-product of normal metabolism. production.

This hypothesis should be presented with explicit caution. Although the biochemistry is coherent, the clinical evidence that CoQ10 depletion causes symptoms, or that repleting CoQ10 relieves them, is directly conflicting. One meta-analysis of twelve randomized trials in 575 patients reported significant improvement in muscle pain, weakness, cramping, and tiredness with supplementation [51], whereas an earlier meta-analysis of six trials in 302 patients and a later analysis of eight trials in 472 patients found no significant benefit [52]; revues systématiquesUne revue systématique recherche toutes les études portant sur une question en utilisant une méthode pré-déclarée, puis les évalue selon des critères cohérents. published through 2025 remain split. Several features of the positive studies reduce confidence in them: sample sizes are small, definitions of muscle symptoms are heterogeneous between trials, and all primary endpoints are subjective and therefore particularly vulnerable to the placebo response that this same literature demonstrates is large.

A more fundamental problem is that the causal chain breaks at its first link. Plasma CoQ10 does fall reliably during statin therapy, but a substantial part of that fall is an artefact of the drug’s intended effect: CoQ10 is transported on lipoproteins, so lowering Nombre de particules de LDLLDL particle number counts how many LDL particles are circulating, rather than how much cholesterol they contain. mechanically lowers measured plasma CoQ10 without necessarily depleting any tissue. What matters for muscle is intramuscular CoQ10, and here the direct measurements are largely reassuring. The LIFESTAT study obtained muscle biopsies from 64 simvastatin-treated patients (25 with myalgia, 39 without) and 20 untreated controls, and found that although statin therapy did impair complex II-linked mitochondrial respiration, intramuscular CoQ10 concentrations were unaltered and myalgia was not coupled to reduced muscle CoQ10 [53]. A double-blind randomized trial of 400 mg daily CoQ10 for eight weeks subsequently found that supplementation did not raise muscle CoQ10 levels, did not improve mitochondrial respiratory capacity, and that individual changes in muscle CoQ10 did not correlate with changes in myalgia intensity [54]. Findings are not uniform — one trial using simvastatin 80 mg reported a 34% fall in muscle CoQ10 — but most biopsy studies have failed to demonstrate clinically meaningful depletion of muscle CoQ10, and the weight of direct tissue evidence therefore does not support depletion as the established mechanism of ordinary statin myalgia.

The practical conclusion is a narrow one, and it should be stated carefully because it is easily misread. Measurable mitochondrial alterations have been demonstrated in statin-exposed muscle in some studies and not in others, and the evidence is discussed further in Section 4.3. What is not established is that CoQ10 depletion causes it, or that oral CoQ10 corrects it. Supplementation is inexpensive and safe and may reasonably be offered empirically, but it should not be described to patients as established therapy, and a patient’s failure to improve on CoQ10 should not be taken as evidence that their symptoms were imaginary. Further adequately powered trials with objective endpoints remain warranted; the existing literature is dominated by small trials with subjective outcomes, which is precisely the design most vulnerable to the placebo response.

Sarcoplasmic reticulum calcium leak

Mitochondrial reactive oxygen species and cellular energy depletion may destabilize sarcoplasmic reticulum ryanodine receptor type 1 (RyR1) channels. Uncontrolled calcium efflux into the cytoplasm activates calpains and caspases, producing myofibrillar degradation and inflammationL'inflammation est la réponse de votre système immunitaire à une blessure ou à quelque chose qu'il traite comme un envahisseur. Elle entraîne gonflement, chaleur et cellules de nettoyage.. Evidence for this mechanism is largely preclinical [50].

4.2 Why non-statin agents spare skeletal muscle

• Acide bempédoïque requires ACSVL1 for prodrug activation. ACSVL1 is undetectable in human skeletal muscle in the published expression work, so the active thioester is not expected to form in myocytes, and muscle mevalonate synthesis, isoprenoid pools, and mitochondrial function are predicted to be spared. That prediction rests on tissue expression data and on the absence of a clinical muscle signal rather than on direct measurement of these downstream pathways in human muscle. This mechanistic prediction has been confirmed clinically: in CLEAR Outcomes, involving 13,970 statin-intolerant patients, myalgia was not increased versus placebo [40].
• PCSK9 monoclonal antibodies and inclisiran: act extracellularly or are targeted to hepatocytes by GalNAc–asialoglycoprotein receptor uptake. Neither is expected to achieve clinically relevant intracellular target engagement in skeletal myocytes or to alter intracellular metabolic pathways there. The same reasoning applies to enlicitide, whose target is likewise the circulating protein.
• Ézétimibe acts at the enterocyte brush border. Ezetimibe and its glucuronide do circulate and undergo enterohepatic recirculation, so the argument is not one of negligible exposure; it is that no skeletal-muscle target has been identified.
• Evinacumab: acts on a circulating protein target within the vascular compartment; no intracellular skeletal-muscle target has been identified.

4.3 Fatigue, Reduced Energy, and Exercise Capacity

Discussion of statin muscle effects is dominated by pain. This is partly an artefact of how outcomes have been defined: the standard SAMS construct centers on myalgia, cramp, and tenderness, and trials that count “muscle symptoms” often capture soreness well and fatigue poorly. Yet in clinical practice a substantial number of patients describe something different — not that their legs hurt, but that they feel flat, that ordinary exertion costs more than it used to, or that training no longer produces the response it once did. These complaints deserve separate treatment, because the evidence bearing on them is different from the evidence on soreness, and in some respects stronger.

Randomized evidence on energy and fatigue

The most direct evidence comes from the UCSD Statin Study, reported by Golomb and colleagues in the Archives of Internal Medicine in 2012. This was a randomized, double-blind, placebo-controlled trial of 1,016 adults without cardiovascular disease or diabèteLe diabète est une affection où la glycémie reste trop élevée, soit parce que l'organisme produit trop peu d'insuline, soit parce qu'il cesse de répondre à l'insuline qu'il produit., with screening LDL-C between 115 and 190 mg/dL, allocated to simvastatin 20 mg, pravastatin 40 mg, or placebo for six months. Participants rated change from baseline in energy and in fatigue with exertion.

Both statins produced significant adverse effects on energy and on exertional fatigue relative to placebo, and the effect was more pronounced in women than in men. This was, to the investigators’ knowledge, the first randomized evidence for an outcome that had previously rested on patient report and observational data. Two features make it particularly relevant here. First, the effect appeared with pravastatin, a hydrophilic statin, as well as with simvastatin — further evidence against a simple lipophilicity hierarchy. Second, the doses were moderate rather than high, so this is not solely a high-intensity phenomenon [60].

The dissociation between subjective energy and objective performance

Against this sits a body of evidence that objective muscle performance is largely preserved. The essai STOMPA randomized, placebo-controlled trial that tested high-dose atorvastatin in healthy, physically active participants; it found increased muscle symptoms and creatine kinase levels but no significant reduction in muscle strength or exercise performance over six months. randomized 420 healthy, statin-naive adults to atorvastatin 80 mg or placebo for six months, with formal measurement of handgrip, elbow and knee strength, knee extensor endurance, and maximal exercice aérobieL'exercice aérobique est une activité soutenue qui vous fait respirer plus fort pendant un certain temps, comme la marche rapide, le vélo, la natation ou le footing. capacity. High-dose atorvastatin produced no significant decrease in average muscle strength or exercise performance. It did increase myalgia (19 versus 10 subjects, P = 0.05), and it increased average creatine kinase by 20.8 U/L (P < 0.0001), with CK rising from baseline in 64.9% of atorvastatin subjects versus 40.1% on placebo. No individual CK value exceeded ten times normal [61,62].

STOMP therefore establishes three things simultaneously that are easily confused. Statins produce a small excess of muscle symptoms. Statins produce measurable biochemical evidence of mild muscle injury even in asymptomatic people. And statins do not, on average, make healthy people measurably weaker or less able to exercise. A patient can accurately report feeling worse while performing objectively the same.

A related observation comes from a physiological study of older male volunteers, which found that statin myalgia was not associated with reduced muscle strength, muscle mass, or protein turnover, but was associated with a slowing of time to peak power output. This suggests that where function is affected, the deficit may lie in the rate at which power can be developed rather than in maximal force — a distinction that conventional strength testing would miss and that patients might experience as heaviness or sluggishness rather than weakness [63].

Exercise training adaptation and mitochondrial capacity

A separate question is whether statins blunt the adaptive response to training rather than baseline performance. Mikus and colleagues randomized 37 sedentary overweight or obese adults with syndrome métaboliqueLe syndrome métabolique est un ensemble de cinq problèmes qui ont tendance à aller de pair : un tour de taille important, des triglycérides élevés, un faible taux de HDL, une tension artérielle élevée et une glycémie élevée. En avoir trois ou plus compte. facteurs de risqueUn facteur de risque est quelque chose qui augmente votre probabilité de développer une maladie : des particules de cholestérol élevées, une tension artérielle élevée, le tabagisme, le diabète, des antécédents familiaux. to 12 weeks of aerobic exercise training alone or exercise plus simvastatin 40 mg daily. Aptitude cardiorespiratoireLa forme cardiorespiratoire correspond à la capacité de votre cœur, de vos poumons et de vos muscles à travailler ensemble pour utiliser l'oxygène lors d'un effort intense. Elle est souvent mesurée par le VO2 max. rose 10% with exercise alone but only 1.5% with exercise plus simvastatin (P < 0.005 for the group-by-time interaction). Skeletal muscle citrate synthase activity, a marker of mitochondrial content measured in vastus lateralis biopsies, rose 13% with exercise alone but fell 4.5% in the statin group (P < 0.05 for interaction) [55].

This finding should be handled with proportion. The sample was small, the population was sedentary and metabolically unwell rather than habitually active, and the agent was simvastatin. A subsequent study of exercise training adaptations in metabolic syndrome patients on chronic statin therapy did not reproduce the same degree of impairment [57]. The finding is nonetheless biologically coherent with direct mitochondrial measurements: a 2024 study reported that high-dose atorvastatin progressively decreased skeletal muscle mitochondrial respiratory capacity in humans, and there is evidence that statin lactone forms inhibit respiratory chain complex III, with reduced complex III activity observed in muscle biopsies from patients with statin-induced myopathy [56,64].

Existing randomized trials largely enrolled sedentary or recreational individuals rather than elite endurance athletes. Whether even small mitochondrial effects become clinically important at elite athletic performance levels remains uncertain. This qualification deserves emphasis rather than a footnote: an effect too small to register on a laboratory strength test in a sedentary cohort is not necessarily too small to matter to someone operating at the limit of their aerobic capacity, where the margins that decide performance are far narrower than the margins that decide statistical significance. The absence of demonstrated harm in trained athletes reflects the absence of adequately powered studies in that population, not evidence of absence.

Whether these findings extend to trained endurance athletes remains uncertain, because subsequent investigations have reported less impairment, and because the populations studied to date have been sedentary and metabolically unwell rather than habitually active. Trained individuals differ in baseline densité mitochondrialeLa concentration de mitochondries au sein des fibres musculaires, qui détermine la capacité de la cellule à produire de l'énergie aérobie ; l'entraînement d'endurance est associé à la préservation de la densité mitochondriale chez les athlètes âgés., training stimulus, and adaptive reserve, and no adequately powered trial has examined statin effects on training adaptation in this group. The Mikus finding should therefore be cited as a signal warranting further study rather than as an established effect in athletes.

The honest summary is that the evidence suggests statins have measurable effects on skeletal muscle mitochondrial function, that these effects have been observed at the tissue and whole-body level in some studies but not others, and that they do not appear to be explained by CoQ10 depletion. For most patients these changes are subclinical. For a minority, and possibly disproportionately for those training at high intensity or already close to their functional ceiling, they may be perceptible.

Étude	Design	Outcome measured	Finding
Golomb et al., Arch Intern Med 2012	RCT, n = 1,016; simvastatin 20 mg vs pravastatin 40 mg vs placebo, 6 months	Self-rated energy and fatigue with exertion	Significant adverse effect on both with both statins; greater in women
STOMP (Parker et al., Circulation 2013)	RCT, n = 420 healthy statin-naive; atorvastatin 80 mg vs placebo, 6 months	Strength, endurance, maximal aerobic capacity, CK	No decrease in strength or exercise capacity; myalgia 19 vs 10 (P = 0.05); mean CK +20.8 U/L (P < 0.0001)
Mallinson et al., J Physiol 2015	Physiological study, older male volunteers	Strength, mass, protein turnover, power output	No reduction in strength, mass, or protein turnover; slowing of time to peak power output
Mikus et al., JACC 2013	RCT, n = 37; 12 weeks training vs training plus simvastatin 40 mg	Cardiorespiratory fitness; muscle citrate synthase	Fitness +10% vs +1.5%; citrate synthase +13% vs −4.5% (both interactions significant)
LIFESTAT (Dohlmann et al., JCEM 2019)	Muscle biopsy study; 64 statin-treated (25 myalgic), 20 controls	Intramuscular CoQ10; mitochondrial respiration	Complex II-linked respiration impaired; muscle CoQ10 unaltered; myalgia not coupled to muscle CoQ10
Kuhlman et al., AntioxidantsAn antioxidant is a substance that mops up damaging molecules in the body. Vitamin E and beta-carotene are examples. 2022	Double-blind RCT, n = 37; CoQ10 400 mg vs placebo, 8 weeks	Muscle CoQ10; mitochondrial function; myalgia	No increase in muscle CoQ10; no improvement in mitochondrial function; no correlation with myalgia
Ryan et al., JCI Insight 2024	Human study of high-dose atorvastatin	Skeletal muscle mitochondrial respiratory capacity	Progressive decrease in respiratory capacity; complex III inhibition implicated

Table 4. Evidence on statin effects on energy, fatigue, and exercise capacity, as distinct from muscle soreness. Note the recurring dissociation: subjective energy and fatigue are affected, objective maximal strength largely is not, and mitochondrial measures are affected without accompanying CoQ10 depletion.

Clinical implications

• Ask about energy, not only pain. A patient who denies muscle soreness may still be experiencing a drug effect. Screening questions should include exertional fatigue, reduced exercise tolerance, and loss of training response.
• Do not equate subjective fatigue with objective weakness. This distinction is a safety matter, not a semantic one. Subjective low energy with normal power and normal CK is a tolerability issue. Objective proximal weakness — difficulty rising from a chair or climbing stairs — particularly with markedly elevated CK, is a red flag for immune-mediated necrotizing myopathy and must be investigated as described in Section 5.2.
• Consider dose and agent before abandoning the class. The fatigue signal in the randomized data appeared at moderate doses of two different statins, so switching alone may not resolve it; dose reduction, intermittent dosing, or a muscle-sparing non-statin agent are all reasonable next steps.
• Counsel patients undertaking new exercise programs realistically. The training-adaptation data are limited and partly conflicting, and should not be used to discourage exercise, which remains strongly beneficial. They do justify taking seriously a patient who reports that training has stopped producing results.
• The nocebo caution applies here too. None of the fatigue evidence exempts these symptoms from the attribution problem described in Section 7. Energy and fatigue are subjective endpoints and were not assessed in the n-of-1 designs, so the proportion of reported statin-associated fatigue that is nocebo-mediated has not been quantified. This is a genuine gap in the literature.

5. The Spectrum of Statin-Associated Muscle Disease

The single most consequential clinical error in this field is treating “statin muscle symptoms” as one entity. There are four biologically distinct phenomena with different frequencies, different mechanisms, and radically different management, with true myopathy and rhabdomyolysis representing two points on a single dose-dependent continuum and shown as separate rows in Table 5. Three are benign or reversible; one is a serious autoimmune disease.

Entity	Définition	Approximate frequency	Behavior on stopping the statin	Management
Nocebo-mediated symptoms	Muscle symptoms attributable to expectation and the act of taking a tablet, not the drug	The large majority of reported symptoms: > 90% of muscle symptom reports on statin were not attributable to the drug (CTT 2022). SAMSON’s nocebo ratio of 0.90 is a different quantity — see Section 7	Resolve, but recur equally with placebo	Blinded or structured rechallenge; explanation; resume statin
Pharmacological myalgia (SAMS)	Symmetrical proximal muscle ache, stiffness, or cramp with CK below 4× ULN	Excess of ≈ 1% over placebo in year 1	Resolve within days to weeks; reproducible on rechallenge	Dose reduction, statin switch, alternate-day dosing, or non-statin agent
True myopathy	Muscle pain or weakness with CK above 10× ULN	≈ 5 per 10,000 treated over five years (0.05%) in the CTT estimate; ≈ 5 per 100,000 person-years in pharmacoepidemiology. Higher figures of 0.1–0.5% appear in older reviews using broader case definitions and are not directly comparable [66]	Resolve on withdrawal	Stop statin; investigate interactions; do not rechallenge at same dose
Rhabdomyolysis	Massive CK elevation with myoglobinuria and acute kidney injury	≈ 4.4 per 100,000 person-years on statin monotherapy [23]; higher with fibrateFibrates are pills that lower triglycerides by making the body break down fat-carrying particles more quickly. combinations	Resolve with supportive care	Emergency; stop statin permanently; IV fluids
Anti-HMGCR immune-mediated necrotizing myopathy	Autoimmune necrotizing myopathy with anti-HMGCR antibodies	≈ 2–3 per million person-years (general population); ≈ 20–25 per million statin users per year	Persists or worsens after withdrawal	Immunosuppression; permanent statin avoidance

Table 5. The entities encompassed by the term “statin muscle symptoms.” Five rows are shown across the four categories used in the abstract, myopathy and rhabdomyolysis being separated here by severity. CK = creatine kinase; ULN = upper limit of normal. The persistence of symptoms after statin withdrawal is the single most useful bedside discriminator for immune-mediated necrotizing myopathy.

Figure 2. The spectrum of statin-associated muscle disease. The entities differ by orders of magnitude in frequency and differ fundamentally in management. Behavior after statin withdrawal is the most useful single discriminator available at the bedside.

5.1 Diagnostic definitions

SAMS / myalgia: subjective muscle pain, aching, stiffness, tenderness, or cramp, typically symmetrical and proximal, affecting thighs, buttocks, and calves, without significant CK elevation [3].

An important corollary follows from that last clause and is frequently misapplied in practice. Creatine kinase is a sensitive marker for myofiber necrosis but an insensitive marker for mild statin-associated muscle symptoms: patients may report severe, genuinely disabling symptoms while CK remains entirely within the reference range. A normal CK therefore makes CK-defined myopathy and rhabdomyolysis very unlikely but does not exclude SAMS, and it is not evidence that the patient’s symptoms are imagined or that the statin is not responsible. CK is a test for dangerous disease, not a test for whether a complaint is real. Conversely, asymptomatic CK elevation is common: in STOMP, CK rose from baseline in 64.9% of patients on atorvastatin 80 mg without accompanying loss of strength.

True myopathy: muscle weakness or pain accompanied by CK exceeding ten times the upper limit of normal. The CTT estimate corresponds to approximately 5 cases per 10,000 patients treated for five years (0.05%), and pharmacoepidemiological analysis gives approximately 5 per 100,000 person-years. Higher figures of 0.1–0.5% cited in older trial reviews reflect broader case definitions and are not directly comparable with either estimate [66].

Rhabdomyolysis: rapid skeletal muscle breakdown with massive CK elevation, hyperkalemia, myoglobinuria, and acute kidney injury from tubular myoglobin cast obstruction. In the largest pharmacoepidemiological analysis, hospitalized rhabdomyolysis occurred at approximately 0.44 per 10,000 person-years, or 4.4 per 100,000, during monotherapy with atorvastatin, pravastatin, or simvastatin, with substantially higher rates for cerivastatin and for statin–fibrate combinations [23]. It occurs most often when high-dose statins are combined with potent CYP3A4 inhibitors, gemfibrozil, or ciclosporin.

5.2 Anti-HMGCR immune-mediated necrotizing myopathy

Statin-associated immune-mediated necrotizing myopathy (IMNM) deserves separate and emphatic treatment, because it is the one statin muscle disease that is genuinely dangerous, is not nocebo, and will be missed if all muscle complaints are attributed to expectation.

IMNM is defined by autoantibodies directed against HMG-CoA reductase itself, the pharmacological target of the drug. The proposed mechanism is that statin exposure upregulates HMGCRHMGCR is the gene for HMG-CoA reductase, the enzyme that performs the rate-limiting step in making cholesterol. It is the exact target of every statin. expression in regenerating muscle fibresLes fibres sont la partie des aliments d'origine végétale que votre corps ne peut pas digérer. On les trouve dans les haricots, l'avoine, les légumes, les fruits et les grains entiers., and in genetically susceptible individuals this drives a sustained autoimmune response that becomes independent of continued drug exposure. It was recognized in the 2018 AHA/ACC Multisociety guideline as a distinct, rare entity [12,68]; that guideline was retired and replaced in March 2026 (Section 9.3).

Reported incidence depends on the denominator used, and both conventions appear in the literature. In the multinational cohort described below, the mean annual incidence was 2.9 cases per million person-years in the general adult population, and 20.4 (UK) to 24.1 (Australia) cases per million statin users per year [67]. Older estimates of approximately 2 per million person-years refer to the general population; figures of 2–3 per 100,000 statin-treated patients refer to statin users. The statin-user denominator is the appropriate one when counseling a patient who is taking the drug, and the general-population denominator understates the risk to that patient roughly tenfold.

A multinational cohort of 109 anti-HMGCR-positive cases reported a median age of 66 years, female predominance of 51%, statin exposure in 101 of 109 patients with atorvastatin accounting for approximately three-quarters, a median statin duration of three years before diagnosis, and a median peak CK of 7,020 IU/L with a range from 964 to 39,076 IU/L. Approximately 7.5% of anti-HMGCR-positive patients had never taken a statin, confirming that the antibody is not exclusively drug-induced [67].

Distinguishing IMNM from SAMS at the bedside

• Weakness dominates over pain. IMNM presents with objective proximal weakness (difficulty rising from a chair, climbing stairs, lifting overhead), whereas SAMS presents with ache and stiffness with preserved power.
• CK is markedly elevated. Typical values are in the thousands to tens of thousands, in contrast to the normal or minimally elevated CK of SAMS.
• Symptoms persist or progress after the statin is stopped. This is the decisive feature. SAMS resolves within days to weeks of withdrawal; IMNM does not.
• Diagnosis requires serology and often histology. Anti-HMGCR antibody testing is highly specific. Muscle MRI demonstrates edema, and biopsy shows myofiber necrosis and regeneration with sparse inflammatory infiltrate.
• Treatment is immunosuppression, not reassurance. Corticosteroids with intravenous immunoglobulin and a steroid-sparing agent such as methotrexate, azathioprine, or rituximab are typically required. Statins must be permanently avoided.

The wider differential: anti-SRP and seronegative IMNM

Anti-HMGCR antibody is not the only serology relevant here, and a negative result does not exclude necrotizing myopathy. IMNM is conventionally divided into three serological groups: anti-HMGCR positive, anti-signal recognition particle (anti-SRP) positive, and seronegative. Approximately 60% of IMNM cases carry either anti-HMGCR or anti-SRP antibodies; the remainder are seronegative and are diagnosed on biopsy [69,70].

• Anti-SRP IMNM is generally not statin-associated and tends to be the more aggressive phenotype. Compared with anti-HMGCR disease it more often produces severe limb weakness, neck weakness, dysphagia, respiratory insufficiency, and muscle atrophy, and it more often involves organs outside muscle, with cardiac involvement and interstitial lung disease both more frequent. Age at onset is typically younger [70].
• Anti-HMGCR IMNM more often presents with muscle weakness alone and without extramuscular involvement. Roughly 7.5% of anti-HMGCR-positive patients are statin-naive, and statin-naive cases differ somewhat from statin-associated ones, occurring more often in younger patients and with higher rates of dysphagia.
• Seronegative IMNM is diagnosed when both antibodies are absent but biopsy shows the characteristic pattern of scattered myofiber necrosis, regeneration, and macrophage-predominant, pauci-lymphocytic inflammation. It carries an elevated association with underlying malignancy, so a negative antibody panel should prompt biopsy and age-appropriate cancer screening rather than reassurance [71].

Outcomes are frequently incomplete despite treatment. In the multinational cohort, fewer than half of patients had a normal CK (47.6%) or normal muscle power (46.2%) at follow-up, and 45.7% had received intravenous immunoglobulin [67]. This refractory course is the clearest argument for recognizing the condition early.

The practical rule that follows is straightforward: any patient with proximal weakness, a CK above ten times the upper limit of normal, or muscle symptoms that fail to resolve within four to six weeks of statin withdrawal should be investigated for necrotizing myopathy rather than reassured about the nocebo effectThe nocebo effect is the placebo effect in reverse: if you expect a medicine to cause a side effect, you are more likely to actually feel it.. If anti-HMGCR is negative and suspicion persists, anti-SRP testing and muscle biopsy are the next steps, not discharge.

6. Relative Muscle Toxicity Profile and Non-Muscle Adverse Effects

Drug class	Muscle toxicity in controlled trials	Mechanistic basis	Principal non-muscle adverse effects
PCSK9 therapeutics (evolocumab, alirocumab, inclisiran, enlicitide)	Not increased above placebo	Extracellular neutralization or GalNAc-directed hepatocyte uptake; no identified intracellular myocyte target	Injection site reactions 2–5%; transient nasopharyngitis; neurocognitive events at placebo rate (EBBINGHAUS) [72]
ACL inhibitors (bempedoic acid)	Not increased above placebo	Prodrug activation requires ACSVL1, undetectable in skeletal muscle	HyperuricemiaAn elevated level of uric acid in the blood, which can precipitate gout and kidney stones; it was identified as a notable adverse effect of bempedoic acid in the CLEAR Outcomes trial, distinguishing its safety profile from that of statins. and gout; reversible creatinine rise; cholelithiasis; tendon rupture; hepatic enzyme elevation
NPC1L1 inhibitors (ezetimibe)	Not increased above placebo. (In GAUSS-3 Phase B, muscle symptoms were reported by 28.8% of ezetimibe recipients and 6.8% discontinued for them; that phase had no placebo arm and enrolled a selected multi-statin-intolerant population, and the placebo-controlled evidence shows no excess.)	Intestinal target; drug and glucuronide do circulate, but no identified skeletal-muscle target	Mild gastrointestinal upset 1–2%, at placebo-level rates
ANGPTL3 inhibitors (evinacumab)	Not increased above placebo	Extracellular protein target; no identified intracellular myocyte target	Infusion-related reactions and hypersensitivity ≈ 6%; nasopharyngitis; influenza-like symptoms
Statins (all agents)	Small but statistically real excess over placebo, confined largely to year 1	Not spared: intracellular HMG-CoA reductase inhibition occurs in myocytes	New-onset diabetes (dose-dependent); transaminase elevation; rare autoimmune hepatitis; rare IMNM

Table 6. Relative muscle toxicity profile of the lipid-lowering drug classes. The classes are presented as descriptive categories rather than as an ordinal ranking, because the non-statin agents are not reliably distinguishable from one another or from placebo on muscle endpoints, and a numbered hierarchy would imply a precision the data do not support. The statin row is deliberately not subdivided by lipophilicity; the rationale is given in Section 6.4. The excess muscle risk attached to statins as a class is small in absolute terms — roughly 11 events per 1,000 person-years in the first year — and should not be read as large merely because it is non-zero.

Table 6 groups agents by class. Because the clinically useful comparison is often between specific agents rather than between classes, the same information is set out below at agent level. Two quantities are separated deliberately, because conflating them is the source of most of the confident but unsupported agent-selection advice in this field. The first column asks whether an agent produces more muscle symptoms than placebo in blinded trials; among the statins, the answer is that they are not reliably distinguishable from one another, which is what the CTT individual participant data found. The second column asks which patients are at elevated risk of genuine, interaction- or genotype-mediated myopathy on a given agent; here the agents differ substantially and predictably. A single ordered ranking would blur the two.

Agent	Muscle symptoms vs placebo in blinded trials	Interaction- and genotype-mediated myopathy risk
PCSK9 monoclonal antibodies (evolocumab, alirocumab)	Not increased	No identified intracellular myocyte target; not applicable
Inclisiran	Not increased	GalNAc-directed hepatocyte uptake; not applicable
Enlicitide	Not increased in the CORALreef program	Circulating protein target; not applicable
ézétimibe	Not increased in placebo-controlled data (see the qualifier in Table 6 regarding GAUSS-3 Phase B)	Enterocyte-local action; not applicable
Acide bempédoïque	Not increased, including in CLEAR Outcomes	ACSVL1 required for activation and undetectable in muscle; not applicable
Evinacumab	Not increased	Extracellular protein target; not applicable
Pitavastatine	Not reliably distinguishable from other statins	Low: minimal CYP450 metabolism; ciclosporin contraindicated
Pravastatin, fluvastatin	Not reliably distinguishable from other statins	Low: non-CYP3A4 disposition; CYP2C9 relevant to fluvastatin
Rosuvastatine	Not reliably distinguishable from other statins	Low to moderate: ABCG2 variants raise exposure; dose caps in Asian ancestry
Atorvastatin, lovastatin	Not reliably distinguishable from other statins	Moderate: CYP3A4-mediated interactions; SLCO1B1 intermediate for atorvastatin
Simvastatin, particularly at 80 mg	Not reliably distinguishable from other statins	Highest among marketed statins: strongest SLCO1B1 signal plus extensive CYP3A4 metabolism; 80 mg no longer recommended
Cérivastatine	Withdrawn 2001	Unacceptable rate of fatal rhabdomyolysis, particularly with gemfibrozil

Table 7. Muscle effects at agent level, with reported symptoms and mechanistic myopathy risk kept in separate columns. The first column reflects blinded randomized data, in which no statin has been reliably distinguished from another on muscle symptom incidence; the entries there should not be read as a ranking. The second column reflects pharmacokinetic and pharmacogenomic exposure, where the agents genuinely differ and where agent selection can be rationalized. The non-statin agents sit at placebo level in the first column and none is reliably distinguishable from the others.

6.1 Bempedoic acid: off-target effects

• Hyperuricemia and gout. Competitive inhibition of renal OAT2 reduces urate excretion, elevating serum uric acid within about four weeks of starting therapy. In CLEAR Outcomes, gout occurred in 3.1% of bempedoic acid recipients versus 2.1% on placebo [40]. Patients with a prior history of gout are at elevated risk of recurrent flares and warrant urate monitoring.
• Reversible creatinine elevation. OAT2 inhibition also reduces tubular creatinine secretion, producing small average rises in serum creatinine and corresponding modest declines in estimated filtration glomérulaireGlomerular filtration is the process by which the kidney's glomeruli — tiny capillary networks — filter waste products and small molecules, including TMAO, from the bloodstream into the urine; adequate glomerular filtration clears fish-derived TMAO within roughly 24 hours, whereas chronic kidney disease reduces this clearance and allows TMAO to accumulate. rate. These changes stabilize early, reverse completely on discontinuation, and reflect transporter competition rather than structural renal injury. They should not be misinterpreted as nephrotoxicity.
• Tendon rupture. An excess of tendon rupture has been observed, involving predominantly the Achilles, rotator cuff, or biceps tendons. Rates were 0.5% versus 0% in the primary hypercholesterolemia trials and 1.2% versus 0.9% in CLEAR Outcomes, so the absolute incidence in treated patients sits at roughly 1% or below across the program, and the excess attributable to the drug is smaller still. The signal is real but uncommon, and it should be presented to patients in those terms rather than as a prominent risk. The proposed mechanism involves altered matrice extracellulaireLa matrice extracellulaire est l'échafaudage de collagène et d'autres fibres qui maintient les tissus ensemble et donne à la paroi artérielle sa résistance. and collagen turnover in tenocytes. Risk factors include age above 60 years, concomitant corticosteroid or fluoroquinolone therapy, renal impairment, and pre-existing tendinopathy [26,41].
• Cholelithiasis and hepatic enzyme elevation. Both were increased in CLEAR Outcomes and warrant awareness, though neither commonly requires discontinuation.

6.2 Statin-associated new-onset diabetes

Statins cause a moderate, dose-dependent increase in new diagnoses of diabetes. The 2024 Cholesterol Treatment Trialists’ Collaboration individual participant data meta-analysis, drawing on the same trial population as the muscle symptom analysis, quantified this precisely. The proportional increase in new-onset diabetes was 10% with low- or moderate-intensity statin therapy (1.3% per year versus 1.2% per year on placebo) and 36% with high-intensity therapy (4.8% versus 3.5% per year) [73].

Two findings put this in proportion. First, the underlying effect is a very small upward shift in glycemia rather than a distinct diabetogenic process: among participants without baseline diabetes, mean glucoseLe glucose est le sucre que votre sang transporte pour alimenter vos cellules. rose by 0.04 mmol/L and mean HbA1c by 0.06% with low- or moderate-intensity therapy and 0.08% with high-intensity therapy. Second, and most importantly for counseling, the excess is concentrated disproportionately among people who were already close to the diagnostic threshold. Among participants with a baseline measure of glycemia, approximately 62% of new-onset diabetes cases occurred in those already in the top quarter of the baseline distribution. That is a clear majority but not the whole of the excess: roughly two in five new diagnoses arose outside the top quarter. The effect is therefore better described as shifting people who were already approaching the threshold across it than as generating diabetes in metabolically healthy people, while acknowledging that a minority of cases do occur at lower baseline glycemia.

One further caveat limits how far the absolute figures travel. The investigators noted that the size of the absolute excess depended substantially on how frequently glycemia was measured in the contributing trials, since new diagnoses are only counted when someone looks for them. The relative estimates are the more transportable quantity; absolute per-1,000 figures for diabetes should be presented to patients as approximations tied to a particular ascertainment regime, not as fixed rates [73].

Genetic evidence indicates this effect is on-target rather than an idiosyncratic drug toxicity. A Randomisation mendélienneMendelian randomization is a clever research method that uses the genes people were born with as a natural experiment. analysis using common variants in HMGCR (rs17238484 and rs12916) as lifelong proxies for HMG-CoA reductase inhibition found that carriers of LDL-lowering alleles had modestly higher bodyweight, tour de tailleLe tour de taille est simplement la mesure de votre milieu, prise au niveau de votre nombril., plasma glucose and insulineL'insuline est une hormone produite par votre pancréas. Son rôle principal est de permettre au sucre de quitter votre sang pour pénétrer dans vos cellules afin de servir de carburant., and a higher risk of type 2 diabetes, closely mirroring the effect observed in the randomized statin trials. The authors concluded that the increased diabetes risk seen with statins is at least partially explained by HMGCR inhibition itself [80].

A further observation complicates any attempt to frame this as a statin-specific liability. Variants in PCSK9 that lower LDL-C are also associated with modestly increased diabetes risk, as are LDL-lowering variants more generally [7,8,91]. The diabetogenic effect may therefore be a property of LDLR-mediated LDL lowering rather than of statins in particular, which would mean it is not avoided by switching to a non-statin agent that works through the same receptor pathway. This remains an inference from genetic épidémiologieL'épidémiologie est l'étude des profils de santé au sein de grands groupes de personnes : qui tombe malade, où, et ce qu'ils ont en commun. and has not been confirmed by outcome trials of the non-statin agents, but it should temper any suggestion that PCSK9 inhibition offers a metabolically free alternative.

Among participants with pre-existing diabetes, the risque relatifLe risque relatif compare deux groupes : ce groupe a enregistré 30 pour cent d'infarctus en moins que cet autre groupe. of worsening contrôle glycémiqueLe contrôle glycémique correspond à la régulation constante de votre glycémie dans une fourchette saine au fil du temps. was 1.10 with low- or moderate-intensity therapy and 1.24 with high-intensity therapy. The investigators emphasized that any adverse cardiovascular consequence of these glycemic changes is already fully captured within the net cardiovascular benefit observed in the same trials. The appropriate response is glycemic monitoring, not statin withholding.

6.3 Hepatic effects, including rare autoimmune hepatitis

Asymptomatic transaminase elevation occurs in roughly 0.5–2% of statin recipients, is usually transient, and does not warrant routine liver function monitoring in asymptomatic patients. Clinically significant statin hepatotoxicity is rare.

A distinct and considerably rarer entity is statin-induced drug-induced autoimmune hepatitis (DIAIH), which mirrors idiopathic autoimmune hepatitis clinically and histologically. It has been documented in case reports and case series for atorvastatin, rosuvastatin, and other agents, and pharmacovigilance analysis of the FDA Adverse Event Reporting System published in 2024 identified positive autoimmune hepatitis signals across all seven marketed statins [75]. Presentation may include jaundice, fatigue, marked transaminase elevation, and positive antinuclear or anti-smooth-muscle antibodies, although seronegative cases occur. Onset ranges from two months to several years after initiation [76].

The clinical parallel with IMNM is instructive and worth stating explicitly: in both conditions, a statin appears to trigger an autoimmune process that can persist after the drug is withdrawn and that requires immunosuppression rather than simple discontinuation. Both are rare. Neither is nocebo. It must be stressed that no reliable incidence estimate exists for statin-induced DIAIH, because the evidence base consists of case reports and disproportionality signals rather than cohort data, and disproportionality signals reflect reporting patterns rather than true frequency. In the context of the enormous global exposure to statins, clinically apparent severe liver injury remains, in the assessment of the NIH LiverTox monograph, extraordinarily rare [74].

6.4 Does lipophilicity predict muscle risk? A qualified answer

It is frequently asserted that lipophilic statins carry a materially higher risk of muscle symptoms than hydrophilic statins, on the reasoning that passive diffusion into myocytes is greater. This review deliberately does not adopt that hierarchy, and the reasons should be set out transparently.

The biological rationale is genuine. Lipophilic agents do achieve greater extrahepatic tissue penetration, and this is a plausible substrate for myocyte injury. However, current randomized evidence has not consistently demonstrated clinically meaningful differences between hydrophilic and lipophilic statins with respect to muscle symptoms. A systematic review and meta-analysis published in 2018 found that statins increased SAMS only slightly overall (relative risk 1.05, 95% CI 1.014–1.089) and that lipophilic statins had no appreciable impact on SAMS development compared with hydrophilic formulations [77]. A network meta-analysis of double-blind randomized trials published in 2022 likewise found no statistically significant difference between individual statins in muscle symptom incidence [78]. The 2022 CTT individual participant data analysis, the largest and most rigorous dataset available, reported no evidence that muscle symptom risk varied among the different statins [65].

Two further sources of evidence bear directly on this. The essai SATURNUn essai comparatif direct par échographie intravasculaire (IVUS) en série comparant la rosuvastatine à 40 mg à l'atorvastatine à 80 mg sur 24 mois ; les deux schémas thérapeutiques ont entraîné une régression de la plaque coronarienne, confirmant qu'un traitement intensif par l'une ou l'autre statine de haute puissance permet d'obtenir des réductions similaires du volume de la plaque. randomized 1,385 patients with coronary disease to rosuvastatin 40 mg (hydrophilic) or atorvastatin 80 mg (lipophilic) for 104 weeks — a head-to-head comparison of the two classes at maximal dose — and found comparable tolerability with no signal of differential muscle toxicity [47]. Separately, the randomized evidence on fatigue discussed in Section 4.3 found adverse effects on energy and exertional fatigue with pravastatin, a hydrophilic agent, as well as with simvastatin.

Three further considerations argue against a simple hierarchy. First, pitavastatin is lipophilic yet has among the lowest interaction-mediated myopathy risk of any statin, because it is barely metabolized by CYP450 enzymes; lipophilicity and clinical risk therefore dissociate. Second, the strongest genuine drug-specific signal is not lipophilicity at all but the SLCO1B1 pharmacogenomic interaction with simvastatin, discussed in Section 8. Third, dose and intensity are more consistent predictors than solubility class: the CTT analysis found a year-one relative risk of 1.11 (95% CI 1.05–1.17) for more intensive regimens compared with placebo, against 1.07 (1.04–1.10) for statin therapy overall.

Underlying all of this is a distinction that is regularly collapsed in discussions of statin intolerance, and which is worth stating explicitly: a mechanistic difference is not a clinical outcome. That lipophilic agents achieve greater extrahepatic tissue penetration is an established pharmacological fact. Whether that difference produces a measurable difference in the rate at which patients report muscle symptoms is a separate empirical question, answerable only by controlled comparison, and the controlled comparisons do not show one. Plausible mechanism is a hypothesis generator, not evidence of effect, and the gap between the two is precisely where a great deal of confident but unsupported prescribing advice in this field originates.

The clinically defensible formulation is therefore this: switching from a lipophilic to a hydrophilic statin is a reasonable and commonly successful individual strategy in a patient who has not tolerated a particular agent, but it should be presented as empirical trial-and-error rather than as a predictable reduction in risk. What does reliably reduce risk is lowering the dose, avoiding interacting drugs, and avoiding high-dose simvastatin.

7. Epidemiology of Reported Muscle Symptoms and the Nocebo Phenomenon

A persistent paradox defines this field. In unblinded observational registries and routine practice, 10–20% of patients report muscle symptoms and many discontinue therapy. In double-blind randomized trials, the difference between statin and placebo is very small. Four bodies of evidence resolve this paradox, and together they constitute one of the more elegant demonstrations of the nocebo effect in modern medicine [81].

Note on the two most-quoted figures in this field: SAMSON’s “90%” and the CTT’s “one in fifteen” are not the same number. They derive from different populations, different metrics, and different study designs, and neither validates the other.

Because these figures are so often conflated, the distinction is worth setting out before either is discussed. The SAMSON nocebo ratio of 0.90 describes the proportion of the increment in symptom intensity caused by taking a tablet that was reproduced by an inert tablet. It was measured in 60 patients who had already abandoned statins because of side effects — a deliberately extreme phenotype — using a continuous daily symptom scale and, critically, a no-tablet control condition that most trials lack. The CTT figure of one in fifteen describes the proportion of reported muscle symptom events in the first year of treatment attributable to the statin rather than to background causes, measured across 123,940 participants in general trial populations by comparing event counts against placebo.

One is a ratio of symptom intensity increments in symptom-prone patients; the other is an attributable fraction of event reports in an unselected population. That they arrive at broadly concordant conclusions — that the large majority of reported statin muscle symptoms are not caused by the drug — is scientifically meaningful precisely because the designs differ so completely. But the numerical closeness of 90% and fourteen-fifteenths is a coincidence of arithmetic, not a replication. Neither figure should be quoted as though it confirmed the other, and neither should be applied to a population unlike the one in which it was measured.

7.1 The Cholesterol Treatment Trialists’ Collaboration meta-analysis (2022)

Le Collaboration CTTThe Cholesterol Treatment Trialists' Collaboration pools the raw data from every major statin trial rather than just comparing published summaries. conducted an individual participant data meta-analysis of 23 large-scale double-blind randomized trials, comprising 19 placebo-controlled trials with 123,940 participants and 4 more-intensive-versus-less-intensive trials with 30,724 participants, published in The Lancet in August 2022 [65].

Over a weighted average median follow-up of 4.3 years, muscle pain or weakness was reported by 16,835 participants allocated to statin (27.1%) versus 16,446 allocated to placebo (26.6%), a rate ratio of 1.03 (95% CI 1.01–1.06). The excess was confined almost entirely to the first year of treatment, during which statin therapy produced a 7% relative increase (rate ratio 1.07, 95% CI 1.04–1.10), corresponding to an absolute excess of 11 events (95% CI 6–16) per 1,000 person-years. After the first year there was no significant excess (rate ratio 0.99, 95% CI 0.96–1.02).

The investigators expressed the implication arithmetically: only one in fifteen of the muscle-related reports among participants allocated to statin therapy was actually attributable to the statin. For more intensive regimens the rate ratio against placebo was 1.08 (95% CI 1.04–1.13) across all years, rising to 1.11 (95% CI 1.05–1.17) in year one, so the attributable fraction rises to roughly one in ten at high intensity. Both of these figures are comparisons against placebo; the four trials that directly randomized more intensive against less intensive therapy yielded a rate ratio of 1.05 (95% CI 0.99–1.11), and the two comparisons should not be conflated. Muscle cramps, a very common reason for discontinuation in practice, showed only a 0.2% absolute difference and are not meaningfully statin-related. Notably, there was no evidence that risk varied between individual statins.

7.2 The SAMSON trial (2020)

SAMSON (Self-Assessment Method for Statin Side-effects Or Nocebo), published in the New England Journal of Medicine in November 2020 with full data in the Journal of the American College of Cardiology in 2021, enrolled 60 patients recruited from 17 UK referral centres and by self-referral, all of whom had previously abandoned statins because of side effects that developed within two weeks of initiation. This is deliberately the most symptom-prone population obtainable [5,6].

Design

SAMSON used a double-blind randomized n-of-1 design spanning 12 consecutive months. Each participant received 12 monthly medication bottles in randomized sequence: four containing atorvastatin 20 mg daily, four containing matching placebo, and four empty. The empty-bottle months are the methodological innovation, since they establish each patient’s background symptom level in the absence of any tablet at all. Participants recorded daily symptom intensity on a smartphone application using a continuous scale from 0 (symptom-free) to 100 (worst imaginable), and could stop that month’s tablets if symptoms became intolerable.

Résultats

Sixty participants were randomized and 49 completed the full 12-month protocol. Mean symptom intensity was 8.0 during no-tablet months (95% CI 4.7–11.3), 15.4 during placebo months (95% CI 12.1–18.7; P < 0.001 versus no-tablet months), and 16.3 during statin months (95% CI 13.0–19.6; P < 0.001 versus no-tablet months). The difference between statin and placebo months was not significant (P = 0.388).

The nocebo ratio, defined as symptom intensity on placebo minus symptom intensity on no tablet, divided by symptom intensity on statin minus symptom intensity on no tablet, was 0.90. Ninety per cent of the symptom burden induced by taking a statin tablet was reproduced by taking a placebo tablet.

One methodological caveat should be recorded for completeness. The originally specified primary analysis produced a nocebo ratio of 2.2 with a 95% intervalle de confianceUn intervalle de confiance est la plage de valeurs qui sont statistiquement compatibles avec ce qu'une étude a révélé. from −62.3 to 66.7, an unstable estimate arising because in some individuals the statin-minus-no-tablet denominator was very small or negative. An independent statistician recommended pooling individual participant data before calculating the ratio, which yielded the reported value of 0.90. This is a legitimate and transparently reported analytical decision, but readers should understand that the headline figure derives from the revised rather than the original analysis.

Tablet stoppages for intolerable symptoms occurred 71 times: 31 during placebo months and 40 during statin months, a non-significant difference. Placebo tablets were therefore abandoned nearly as often as active drug. At six-month follow-up, after participants were shown individualized charts of their own symptom scores across the three conditions, 30 of the 60 participants had successfully restarted statin therapy.

7.3 The StatinWISE trial (2021)

StatinWISE, published in the BMJ in February 2021, independently replicated SAMSON at larger scale in primary care. It comprised a series of 200 randomized double-blind n-of-1 trials in patients considering discontinuation because of muscle symptoms, using atorvastatin 20 mg versus placebo across six two-month periods [82].

Of 200 participants, 151 (75.5%) contributed to the primary analysis. There was no difference in muscle symptom scores between statin and placebo periods (mean difference −0.11, 95% CI −0.36 to 0.14; P = 0.40). Withdrawal for intolerable muscle symptoms occurred in 9% during statin periods and 7% during placebo periods. Two-thirds of participants who completed the trial elected to resume statin therapy. The convergence of two independently conducted n-of-1 programs on the same conclusion materially strengthens the inference.

7.4 ASCOT-LLA: blinded versus unblinded (2017)

The most compelling population-level evidence comes from a natural experiment within a single trial. ASCOT-LLA randomized patients to atorvastatin 10 mg or placebo in a blinded phase, then continued them in a non-blinded extension in which patients and physicians knew who was taking a statin.

During the blinded randomized phase there was no significant excess of muscle-related adverse events on atorvastatin. During the non-blinded extension, muscle-related adverse events were significantly more frequent among statin users (161 events, 1.26% per year) than non-users (124 events, 1.00% per year), a relative risk of 1.41 (95% CI 1.10–1.79; P = 0.006). The drug did not change. Only the knowledge of taking it changed [83].

7.5 GAUSS-3: quantifying genuine intolerance (2016)

GAUSS-3, published in JAMA in April 2016, is the necessary counterweight to the nocebo literature, because it demonstrates that genuine pharmacological intolerance is also real. It enrolled 511 patients with a documented history of intolerance to two or more statins and entry mean LDL-C of approximately 212 mg/dL [42].

Phase A: blinded rechallenge

491 patients underwent a 24-week double-blind crossover rechallenge with atorvastatin 20 mg versus placebo, 10 weeks each, separated by washout. The results partition this heavily preselected population into four groups: 209 of 491 (42.6%) developed intolerable muscle symptoms on atorvastatin but not placebo; 26.5% developed symptoms on placebo but not atorvastatin; approximately 10% developed symptoms on both; and the remainder on neither. During the second crossover period the rapport des cotesUn rapport des risques instantanés compare la rapidité avec laquelle les événements se produisent dans deux groupes. Un rapport de 0,75 signifie que les événements se sont produits à un rythme égal aux trois quarts dans le groupe traité. for muscle symptoms on atorvastatin versus placebo was 1.96 (95% CI 1.44–2.66; P < 0.001).

Two conclusions follow, and both matter. Genuine, reproducible, pharmacologically mediated statin intolerance exists and affected roughly 43% of this extreme-phenotype population. Equally, more than a quarter of these same patients experienced intolerable muscle pain caused entirely by an inert tablet. Framed the other way, approximately 60% of patients who had already failed at least two statins did not demonstrate reproducible intolerance on blinded rechallenge.

Phase B: comparative non-statin therapy

218 patients with confirmed intolerance, comprising those identified in Phase A plus 19 who bypassed Phase A because of documented prior CK elevation above ten times the upper limit of normal, were randomized 2:1 to evolocumab 420 mg monthly (n = 145) or ezetimibe 10 mg daily (n = 73) for 24 weeks.

Two co-primary endpoints were reported. From baseline to week 24, LDL-C fell 52.8% with evolocumab versus 16.7% with ezetimibe. For the mean of weeks 22 and 24, LDL-C fell 54.5% (95% CI −57.2 to −51.8; absolute reduction 103.6 mg/dL) with evolocumab versus 16.7% (95% CI −20.5 to −12.9) with ezetimibe, a between-group difference of −37.8% (95% CI −42.3 to −33.3; P < 0.001). Muscle symptoms were reported by 20.7% of evolocumab recipients and 28.8% of ezetimibe recipients. Discontinuation for intolerable muscle symptoms occurred in 1 of 145 patients (0.7%) on evolocumab versus 5 of 73 (6.8%) on ezetimibe. Neither arm had a placebo comparator, so these rates quantify residual symptom burden in a selected population rather than drug-attributable risk [42].

Exploratory genomics

Exploratory genome-wide analysis within GAUSS-3 identified associations between statin-associated muscle symptoms and loci at MGAT5 et KCNJ2/SOX9, while variants influencing systemic statin exposure such as SLCO1B1 were not significantly associated with symptom recurrence in this cohort. These findings are hypothesis-generating only: the cohort comprised roughly 500 patients, which is severely underpowered for genome-wide discovery, and the loci have not been robustly replicated. They should not be presented to patients as clinically actionable.

Trial	Design and population	Principale conclusion
CTT Collaboration (2022)	19 placebo-controlled double-blind RCTs; 123,940 participants; median 4.3 years	27.1% vs 26.6% reported muscle symptoms (RR 1.03); year-1 RR 1.07, excess 11 per 1,000 person-years; only 1 in 15 reports attributable to statin
SAMSON (2020)	Double-blind n-of-1; 60 patients who had abandoned statins; 4 statin, 4 placebo, 4 empty months	Symptom scores 8.0 / 15.4 / 16.3 (no tablet / placebo / statin); statin vs placebo P = 0.388; nocebo ratio 0.90; 30 of 60 restarted
StatinWISE (2021)	200 double-blind n-of-1 trials in primary care; atorvastatin 20 mg vs placebo	No difference in symptom score (mean difference −0.11, 95% CI −0.36 to 0.14); two-thirds of completers resumed statins
ASCOT-LLA (2017)	Blinded randomized phase vs non-blinded extension of the same trial	No excess muscle events when blinded; RR 1.41 (95% CI 1.10–1.79) when unblinded
GAUSS-3 (2016)	511 multi-statin-intolerant patients; blinded atorvastatin rechallenge then evolocumab vs ezetimibe	42.6% symptoms on statin only; 26.5% on placebo only; evolocumab −54.5% vs ezetimibe −16.7% LDL-C

Table 8. Landmark trials defining the boundary between pharmacological and nocebo-mediated statin muscle symptoms. RR = rate ratio or relative risk as reported by the original investigators.

7.6 Putting Benefit and Harm on the Same Scale

Relative risks and rate ratios are the natural language of trial reporting but a poor basis for a conversation with a patient, who is deciding about one person rather than a cohort. The quantities that matter to that decision are absolute, and the CTT Collaboration has published them for a standard regimen.

Lowering LDL-C by 2 mmol/L (77 mg/dL) with an effective regimen such as atorvastatin 40 mg daily, for five years in 10,000 patients, would typically prevent one or more major vascular events in about 1,000 patients with pre-existing occlusive vascular disease, an absolute benefit of 10%, and in about 500 patients at elevated risk who have not yet had an event, an absolute benefit of 5%. Against this, the same treatment in the same 10,000 patients over the same period would typically cause about 5 cases of myopathy, of which one might progress to rhabdomyolysis if the statin were not stopped, 50 to 100 new cases of diabetes, and 5 to 10 hemorrhagic strokesUn accident vasculaire cérébral hémorragique est un type d'accident vasculaire cérébral provoqué par un saignement dans ou autour du cerveau plutôt que par une artère obstruée ; l'aspirine altérant la coagulation, elle augmente le risque de cette complication, ce qui est une raison majeure pour laquelle son utilisation chez les individus à faible risque est désormais déconseillée., alongside symptomatic adverse events such as muscle pain in up to 50 to 100 patients, an absolute harm of 0.5% to 1.0% [2].

Outcome over 5 years	Per 10,000 treated	Per 1,000 treated	Absolute rate
Major vascular events prevented, prévention secondaireLa prévention secondaire consiste à traiter une personne ayant déjà eu une crise cardiaque, un accident vasculaire cérébral ou la pose d'un stent, afin d'en empêcher une récidive.	≈ 1,000	≈ 100	10% benefit
Major vascular events prevented, primary prevention	≈ 500	≈ 50	5% benefit
New-onset diabetes caused	50–100	5–10	0.5–1.0% harm
Symptomatic muscle adverse events caused	50–100	5–10	0.5–1.0% harm
Hemorrhagic cajoleriesUn accident vasculaire cérébral se produit lorsque le flux sanguin vers une partie du cerveau s'arrête, soit en raison d'un blocage, soit d'une hémorragie. causé	5–10	0.5–1	0.05–0.1% harm
Myopathy caused (CK > 10× ULN)	≈ 5	≈ 0.5	0.05% harm
Rhabdomyolysis caused	≈ 1	≈ 0.1	0.01% harm

Table 9. Absolute benefit and harm from five years of an effective statin regimen lowering LDL-C by 2 mmol/L, per CTT Collaboration estimates. Per-1,000 figures are derived by division and are given for accessibility; the published estimates are per 10,000. Benefits scale with baseline risque absoluLe risque absolu est la probabilité réelle que quelque chose vous arrive, exprimée en pourcentage. Si votre risque absolu de faire une crise cardiaque au cours des dix prochaines années est de 12 pour cent, cela signifie qu'environ 12 personnes sur 100 ayant le même profil que vous en feraient une. and with the magnitude and duration of LDL-C reduction, so these figures describe a typical patient rather than any individual one. Two rows require qualification. The new-onset diabetes row derives from the same earlier five-year projection and should be read as an order-of-magnitude estimate: the 2024 individual participant data analysis found that the absolute excess varied substantially with the intensity of glycemic ascertainment across trials, so no single fixed absolute figure is well supported (Section 6.2). The symptomatic muscle adverse event row likewise derives from the CTT group’s earlier five-year projection. The 2022 individual participant data analysis reported an absolute excess of 11 events per 1,000 person-years confined to the first year, equivalent to approximately 110 per 10,000 in year one alone, and supersedes the earlier projection for this endpoint. The two estimates use different definitions and time bases and should not be added, averaged, or read as inconsistent benefit accounting.

Three features of this comparison deserve emphasis. The benefits and harms are not of equal weight even where the numbers are similar: myopathy and muscle symptoms reverse on stopping the drug, whereas infarctus du myocardeVoir Crise cardiaque pour l'article complet. and stroke frequently do not. Any adverse cardiovascular consequence of the excess diabetes and hemorrhagic stroke is already contained within the net benefit figures, because both arose in the same trials from which the benefit was measured, so the columns should not be subtracted from one another. And the benefit accrues for each year treatment continues, so five years understates what lifelong therapy achieves.

The honest counterweight is that these estimates come from the CTT group, whose methods and access to individual participant data have been contested by a minority of investigators, and that they describe populations rather than persons. A patient at very low absolute cardiovascular risk gains proportionally less, and for that patient the balance is genuinely closer than the table suggests.

8. Pharmacogenomics of Statin Myopathy

If the question is which patient is most likely to sustain genuine muscle injury on a statin, the most robust answer available is genetic rather than physicochemical.

8.1 SLCO1B1

The defining discovery was a genome-wide association study within the SEARCH trial, published in the New England Journal of Medicine in 2008, which identified the SLCO1B1 c.521T>C variant (rs4149056) as the dominant genetic determinant of myopathy with simvastatin 80 mg [79]. SLCO1B1 encodes OATP1B1, the hepatic uptake transporter. Reduced-function variants impair hepatic extraction, raising systemic exposure to statin acid and increasing skeletal muscle exposure.

Guidance is provided by the Clinical Pharmacogenetics Implementation Consortium (CPIC), whose 2022 guideline covers SLCO1B1, ABCG2, et CYP2C9 genotypes and statin-associated musculoskeletal symptoms, superseding the earlier simvastatin-only guideline [22]. The evidence linking rs4149056 to myopathy is graded as high quality for simvastatin. CPIC recommends dose limitation or selection of an alternative statin in decreased- and poor-function phenotypes. Allele function assignments were further updated in October 2025 to improve accuracy in under-represented populations [84].

The association is strongly drug-specific, which is clinically useful. It is strongest for simvastatin, intermediate and less consistent for atorvastatin, and minimal for pravastatin, rosuvastatin, fluvastatin, and pitavastatin, because OATP1B1 contributes a different proportion of hepatic uptake for each agent.

8.2 ABCG2, CYP2C9, and other loci

• ABCG2: encodes the efflux transporter BCRP. The c.421C>A variant markedly increases rosuvastatin exposure, and CPIC 2022 includes rosuvastatin dosing recommendations by ABCG2 phenotype [22].
• CYP2C9: the principal metabolizing enzyme for fluvastatin; poor metabolisers accumulate drug and warrant dose limitation.
• CYP3A4*22: reduced-function allele affecting simvastatin, lovastatin, and atorvastatin clearance. Evidence is suggestive but not yet guideline-actionable.
• COQ2, GATM, and the GAUSS-3 loci (MGAT5, KCNJ2/SOX9): candidate associations with inconsistent replication. These remain research findings and should not be used clinically.

Gene	Variant	Statins principally affected	Practical implication
SLCO1B1	c.521T>C (rs4149056)	Simvastatin (strong); atorvastatin (moderate)	Avoid high-dose simvastatin in decreased/poor function; prefer rosuvastatin, pravastatin, fluvastatin, or pitavastatin
ABCG2	c.421C>A	Rosuvastatine	Limit rosuvastatin dose in poor-function phenotypes
CYP2C9	*2, *3 reduced-function alleles	Fluvastatine	Limit fluvastatin dose in poor metabolisers
CYP3A4	*22	Simvastatin, lovastatin, atorvastatin	Suggestive only; not currently guideline-actionable
MGAT5, KCNJ2/SOX9, COQ2, GATM	Various	Not agent-specific	Exploratory; not clinically actionable

Table 10. Pharmacogenomic loci relevant to statin myopathy, with recommendations following the CPIC 2022 guideline (updated October 2025). Only SLCO1B1, ABCG2, and CYP2C9 currently carry actionable CPIC recommendations.

8.3 Drug-drug interactions

Interaction-mediated myopathy is more common, more predictable, and more preventable than idiosyncratic myopathy. The mechanism is straightforward: anything that raises systemic statin concentration raises muscle exposure.

Interacting agent	Mécanisme	Statins affected	Management
Gemfibrozil	Inhibits glucuronidation and OATP1B1 transport	All statins	Avoid combination; use fenofibrate instead if a fibrate is required
Clarithromycin, erythromycin, itraconazole, ketoconazole, ritonavir	Potent CYP3A4 inhibition	Simvastatin, lovastatin, atorvastatin	Suspend statin during short courses, or switch to pravastatin, rosuvastatin, or pitavastatin
Ciclosporin	OATP1B1 and multi-transporter inhibition	All; contraindicated with pitavastatin	Strict dose caps; specialist supervision
Amiodarone, verapamil, diltiazem	Moderate CYP3A4 inhibition	Simvastatin, lovastatin	Dose caps per labeling; consider a non-CYP3A4 statin
ColchicineLa colchicine est un vieux médicament anti-inflammatoire bon marché, utilisé depuis des siècles contre la goutte, et qui est aujourd'hui réorienté vers le traitement des maladies cardiaques.	Independent myotoxicity; additive risk	All statins	Monitor CK if used together, especially in renal impairment
Grapefruit juice (large quantities)	Intestinal CYP3A4 inhibition	Simvastatin, lovastatin, atorvastatin	Advise moderation; clinically relevant mainly at high intake

Table 11. Clinically important drug interactions increasing statin myopathy risk. Note that pravastatin, rosuvastatin, and pitavastatin share the advantage of minimal CYP450 metabolism, which is a more reliable basis for statin selection in polypharmacy than lipophilicity.

8.4 Reversible non-genetic contributors

Before concluding that a patient is statin-intolerant, several reversible contributors should be excluded, since each independently produces or amplifies myalgia: hypothyroidism (check TSH), vitamin D deficiency, renal impairment, recent unaccustomed vigorous exercise, and excess alcoolAlcohol is the ingredient in beer, wine, and spirits that makes them intoxicating. intake [58]. One qualification is worth recording: although vitamin D deficiency is commonly corrected in this setting, a randomized comparison of vitamin D against placebo in new statin users found no reduction in statin-associated muscle symptoms, so repletion should be regarded as reasonable general care rather than as a demonstrated remedy for SAMS [85]. Advanced age, low body mass, female sex, and Asian ancestry (particularly relevant to rosuvastatin dosing) also increase susceptibility.

9. Clinical Management: An Evidence-Based Algorithm

The following sequence integrates the evidence reviewed above. Its guiding principle is that the patient’s symptoms should always be taken seriously, while causal attribution to the drug should not be assumed [58,81].

Figure 3. Management algorithm for reported statin muscle symptoms. The sequence is deliberate: dangerous disease is excluded before attribution is discussed, because a patient with immune-mediated necrotizing myopathy who is reassured about the nocebo effect may deteriorate.

1. Exclude dangerous myopathy first. Measure CK. If CK exceeds ten times the upper limit of normal, or if there is objective proximal weakness, or if there is dark urine or renal impairment, stop the statin immediately and investigate for true myopathy, rhabdomyolysis, or immune-mediated necrotizing myopathy. Do not proceed to reassurance about nocebo until this step is complete.
2. Identify reversible contributors. Review for interacting drugs, hypothyroidism, vitamin D deficiency, renal impairment, and recent unaccustomed exertion. Correct what is correctable.
3. Dechallenge and rechallenge. Withdraw the statin for two to four weeks. Failure to improve lowers the likelihood of ordinary pharmacological SAMS and should prompt reassessment for alternative causes or for a persistent myopathy, rather than a presumption that the statin was blameless; if symptoms persist beyond four to six weeks, particularly with elevated CK or objective weakness, investigate for IMNM. If symptoms do resolve, rechallenge with a different statin at a low dose.
4. Use structured or blinded rechallenge where feasible. SAMSON and StatinWISE demonstrate that objective, individualized data on a patient’s own symptom pattern is an effective intervention for restoring adhésionL'observance thérapeutique consiste à prendre réellement ses médicaments de la manière prescrite, jour après jour. — the one with the most direct randomized support — enabling roughly half to two-thirds of participating patients to resume therapy. Neither trial compared this approach against other adherence strategies, so it should not be described as superior to all alternatives [5,6,82].
5. Modify the regimen before abandoning the class. Reduce the dose; switch agent, particularly away from high-dose simvastatin; or use alternate-day or twice-weekly dosing of a long-half-life statin such as rosuvastatin or atorvastatin. Any tolerated statin dose confers benefit; partial tolerance is not failure.
6. Add a muscle-sparing agent to a reduced statin dose. Ezetimibe is inexpensive, well tolerated, and adds 15–20%. Bempedoic acid adds approximately 18% and is the only non-statin oral agent with proven cardiovascular outcome benefit in statin-intolerant patients.
7. Escalate to PCSK9-directed therapy for confirmed intolerance with substantial risque résiduelLe risque résiduel est le risque qui subsiste après avoir fait ce qui est évident — cholestérol traité, tension artérielle contrôlée, non-tabagisme.. GAUSS-3 validated evolocumab in this exact population, and inclisiran offers twice-yearly dosing where adherence is the limiting factor.
8. Consider genotyping in recurrent intolerance. SLCO1B1, ABCG2, et CYP2C9 genotyping per CPIC 2022 can rationalize agent selection after two or more failures.
9. Document formally. Statin intolerance should be documented against the National Lipid Association definition, which requires trial of at least two statins including one at the lowest approved dose, rather than recorded on the basis of a single failed trial [4].

9.1 Communicating risk to patients

Evidence from SAMSON indicates that showing patients their own data is more persuasive than citing population statistics. Where individualized n-of-1 data are unavailable, the following framings are accurate and useful: muscle aches are common in adults regardless of medication, and roughly a quarter of people report them whether taking a statin or a placebo; of every fifteen people who report muscle symptoms on a statin, about fourteen would have had them anyway [65]; most symptoms genuinely caused by a statin appear within the first year and resolve within weeks of stopping, although later onset does occur in individuals; and a substantial majority of people who stop a statin because of symptoms and are willing to try again can successfully restart one. That last figure comes from patients who volunteered for rechallenge and should not be quoted as a rate for all discontinuers.

Equally important is what should not be said. Symptoms should never be described as imaginary. The nocebo effect produces real, measurable symptoms; SAMSON participants abandoned placebo tablets nearly as often as active drug. The message is that the symptoms are real but their cause is usually not the drug, and that this distinction opens a path back to treatment rather than closing one.

9.2 Objective diagnostics

• Routine monitoring in asymptomatic patients is not recommended. Obtain a baseline in patients at elevated risk, and measure in any symptomatic patient. CK above ten times the upper limit of normal defines myopathy and mandates discontinuation. Note the asymmetry in what the result tells you: an elevated CK is informative, but a normal CK is not reassurance that symptoms are absent or imagined. CK is insensitive for mild SAMS, and patients with disabling symptoms frequently have entirely normal values.
• Anti-HMGCR antibodies. Test when weakness is prominent, CK is markedly elevated, or symptoms persist beyond four to six weeks after withdrawal.
• Muscle MRI and biopsy. Reserve for suspected inflammatory or necrotizing myopathy, typically after positive or equivocal serology.
• TSH, vitamin D, renal function. Obtain in all patients presenting with muscle symptoms on a statin.
• SAMS Clinical Index. A standardized causality instrument that scores symptom location, timing of onset after initiation, and timing of resolution after withdrawal, useful for consistent documentation [86].

9.3 Guideline context: the 2026 dyslipidemia guideline

The framework surrounding the decisions above changed in March 2026. The 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia retires and replaces the 2018 Guideline on the Management of Blood Cholesterol, and is retitled to reflect attention to atherogenic lipoproteins beyond LDL particles, including triglyceride-rich remnants and lipoprotein(a) [11]. Five changes bear on this review.

• Risk estimation. The AHA PREVENT-ASCVD equations replace the Équations de cohorte regroupéesLes Pooled Cohort Equations sont l'outil de calcul du risque actuellement recommandé par l'American College of Cardiology et l'American Heart Association, qui estime vos probabilités sur dix ans de faire une crise cardiaque ou un accident vasculaire cérébral à partir de l'âge, du taux de cholestérol, de la tension artérielle, du diabète et du statut tabagique. for guiding lipid-lowering therapy in primary prevention in adults aged 30 to 79, providing both 10-year and 30-year risk projections.
• Treatment goals return. LDL-C and non-HDL-C goals are restored alongside percentage reduction. The guideline sets an LDL-C goal below 100 mg/dL at borderline or intermediate risk, below 70 mg/dL at high risk, and below 55 mg/dL for patients with clinical ASCVD at very high risk. This is a material change from the 2018 framework, which prioritized statin intensity over absolute targets, and it strengthens the case for combination therapy in patients who do not reach goal on a statin alone.
• ApoBL'ApoB est une protéine située à la surface de chaque particule de cholestérol susceptible de se coincer dans la paroi de vos artères et de provoquer de la plaque. Chacune de ces particules transporte exactement une ApoB. and Lp(a). ApoB testing is described as useful once LDL-C and non-HDL-C goals are met, particularly with triglycerides above 200 mg/dL, diabetes, or achieved LDL-C below 70 mg/dL. Lp(a) should be measured at least once in adults as part of risk assessment.
• Non-statin sequencing. Where statin therapy alone does not achieve goal, ezetimibe, bempedoic acid, and PCSK9 monoclonal antibodies are the recommended additions. Inclisiran recommendations were held pending its outcome trials, which is consistent with the distinction drawn in Section 11.
• Statin intolerance. The guideline includes a practical algorithm for statin intolerance, which is the context in which the management sequence in Section 9 should be read.

Two points of interpretation follow for this review. The intensity classification in Table 2 remains useful and percentage LDL-C reduction remains a stated priority, so nothing in Section 3 is invalidated. But the goal-based structure changes the practical weight of the muscle symptom problem: when a patient must reach an absolute LDL-C target rather than simply tolerate a statin of a given intensity, correctly distinguishing nocebo-mediated from pharmacological intolerance becomes more consequential, not less, because unnecessary discontinuation now forecloses a defined therapeutic goal rather than an intensity category.

10. Emerging Therapeutics

REGULATORY STATUS MUST BE VERIFIED IMMEDIATELY BEFORE CLINICAL USE OR PUBLICATION. Approval status, trial readouts, and labeling in this field change on a timescale of months. Status below reflects information verified to 9 August 2026. Obicetrapib and the lipoprotein(a)-directed agents remain investigational for the indications described. Enlicitide is no longer investigational — it was approved in July 2026 — but its cardiovascular outcome data are still pending, and that distinction is maintained throughout this section.

All figures in this section are surrogate endpointA surrogate endpoint is a measurable biological marker — such as LDL cholesterol, CIMT, or coronary artery calcium — used in trials as a stand-in for a clinical outcome like a heart attack; favorable changes in surrogates support plausibility of benefit but do not by themselves prove that a treatment prevents heart attacks or death. data. None of these agents, approved or not, has completed a cardiovascular outcomes trial for the use described, and LDL-C or lipoprotein(a) reduction must not be presented to patients as demonstrated event reduction. Regulatory approval on a lipid endpoint is not the same thing as demonstrated event reduction, and the two should be kept apart in patient conversations.

10.1 Obicetrapib (oral CETP inhibitor)

Phase 3 BROADWAY and TANDEM results were published in 2025 and presented at the European AthéroscléroseL'athérosclérose est la maladie à l'origine de la plupart des crises cardiaques et de nombreux accidents vasculaires cérébraux. Des particules de cholestérol se coincent dans la paroi d'une artère, le corps envoie des cellules immunitaires pour nettoyer, et au fil des ans, ce désordre durcit pour former de la plaque. Society Congress. Added to maximally tolerated background therapy, obicetrapib 10 mg reduced LDL-C by approximately 33–37% versus placebo, with a fixed-dose combination with ezetimibe achieving approximately 50%. The agent also lowers lipoprotein(a) and apolipoprotein B, and safety was comparable to placebo across the program. The PREVAIL cardiovascular outcomes trial randomized more than 9,500 patients and completed enrollment in April 2024, with results anticipated in late 2026. On 23 July 2026 the EMA Committee for Medicinal Products for Human Use adopted positive opinions recommending marketing authorization for obicetrapib monotherapy (Ubeslo) and the obicetrapib–ezetimibe fixed-dose combination (Evlarco) in primary hypercholesterolemia and mixed dyslipidemia; the European Commission decision remains pending [87,88]. A positive opinion is a regulatory step, not outcome evidence, and PREVAIL remains the trial that will determine whether LDL-C lowering by CETP inhibition reduces events. Historical caution is warranted for the CETP class given the failures of torcetrapib, dalcetrapib, and evacetrapib [38].

10.2 Enlicitide (oral PCSK9 inhibitor) — approved July 2026

Enlicitide is an orally bioavailable macrocyclic peptide that binds PCSK9 and blocks its interaction with the LDL receptor. It was approved by the FDA on 16 July 2026, marketed as Lipfendra, as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia including heterozygous familial hypercholesterolemia. It is the first oral PCSK9 inhibitor to reach the market [36]. The dose is a 20 mg tablet once daily, taken on an empty stomach, with a required interval before food.

Approval rested on two phase 3 trials in the CORALreef program. CORALreef Lipids randomized 2,904 adults on stable moderate- or high-intensity statin therapy who required further LDL-C reduction, and CORALreef HeFH applied the same design in 303 patients with heterozygous familial hypercholesterolemia. At 24 weeks, placebo-adjusted LDL-C reductions were approximately 56% and 59% respectively. Adverse events were broadly comparable with placebo in CORALreef Lipids; in the smaller HeFH trial, diarrhea and dizziness were reported more often than with placebo [44,45].

Two qualifications matter for how this agent is discussed with patients. First, approval was granted on an LDL-C endpoint; the CORALreef Outcomes cardiovascular trial is ongoing, with results not expected until around 2029 [46], so event reduction is anticipated on mechanistic grounds but not yet demonstrated for this agent. The distinction drawn in Section 11 between agents with and without outcome evidence therefore applies to enlicitide as it does to inclisiran. Second, the relevance to this review is specific: an oral agent achieving monoclonal-antibody-magnitude LDL-C reduction removes both the injection barrier and any plausible route of skeletal muscle exposure, which makes it a substantive addition to the options available in confirmed statin intolerance. Post-marketing tolerability characterization remains at an early stage.

10.3 Lipoprotein(a)-directed therapies

Lipoprotein(a) is a genetically determined, causal cardiovascular risk factor essentially unaffected by statins, ezetimibe, or lifestyle modification. Several nucleic acid therapies achieve profound reduction: pelacarsenPelacarsen is an RNA-targeted therapy (an antisense oligonucleotide) designed to lower lipoprotein(a) by reducing its production in the liver; it is given by intravenous or subcutaneous injection every few weeks and is currently in late-stage trials to determine whether Lp(a) reduction translates into fewer cardiovascular events. (antisense oligonucleotide, Lp(a) HORIZON outcomes trial), olpasiranOlpasiran is a small-interfering RNA (siRNA) drug in phase 3 clinical development that dramatically reduces circulating Lp(a) levels by silencing the gene responsible for its production in the liver. (siRNA, greater than 95% reduction in phase 2, OCEAN(a)-Outcomes ongoing) [89], lepodisiran (siRNA, a placebo-adjusted time-averaged reduction of 93.9% across days 60 to 180 after a single 400 mg dose in the ALPACA phase 2 trial published in 2025) [90], zerlasiran, and the oral small molecule muvalaplin. None has yet demonstrated event reduction, and outcome trial readouts are anticipated from 2026 onward. These agents are included here for completeness of the lipid-lowering landscape rather than as current therapy.

11. Synthesis

Managing lipid disorders requires balancing aggressive LDL-C lowering against perceived and genuine drug toxicity. Eight conclusions follow from the evidence reviewed.

1. Reported muscle symptoms are usually not caused by the statin. Two independent lines of evidence converge on this. In patients who had already abandoned statins, roughly 90% of the symptom burden induced by taking a tablet was reproduced by an inert tablet (SAMSON). In unselected trial populations, only about one in fifteen reported muscle symptom events in the first year was attributable to the drug, with no excess thereafter (CTT). As set out in Section 7, these are different measures in different populations and should be cited as convergent rather than identical.
2. Genuine pharmacological intolerance nonetheless exists. GAUSS-3 demonstrated reproducible, blinded, drug-specific muscle symptoms in 42.6% of an extreme-phenotype population, and the CTT analysis confirms a small but statistically real excess.
3. A rare autoimmune myopathy must never be missed. Anti-HMGCR immune-mediated necrotizing myopathy occurs at roughly 20 to 25 cases per million statin users per year (about 2–3 per million person-years in the general population), presents with weakness and marked CK elevation, persists after drug withdrawal, and requires immunosuppression.
4. Muscle effects extend beyond soreness. Randomized data show adverse effects on energy and exertional fatigue at moderate doses of both a lipophilic and a hydrophilic statin, and statins measurably affect skeletal muscle mitochondrial function. Objective maximal strength and exercise capacity are nonetheless largely preserved, and none of these effects is explained by coenzyme Q10 depletion.
5. Muscle-sparing alternatives exist and are mechanistically justified. Bempedoic acid, PCSK9 inhibitors, inclisiran, and ezetimibe all avoid myocyte exposure by distinct routes. Their outcome evidence differs sharply, however, and should not be blurred: the PCSK9 monoclonal antibodies and bempedoic acid have demonstrated cardiovascular event reduction, ezetimibe has done so as add-on therapy, whereas inclisiran has demonstrated LDL-C reduction only. Its cardiovascular outcome trials, ORION-4 and VICTORION-2P, remain ongoing, and inclisiran should be described to patients as an agent of proven lipid effect and as yet unproven event reduction. The same applies to enlicitide, approved in July 2026 on an LDL-C endpoint with CORALreef Outcomes still running.
6. Statin selection should be driven by interaction profile and pharmacogenomics rather than by lipophilicity. The strongest actionable signal is SLCO1B1 with simvastatin; the most reliable practical lever is avoiding CYP3A4-mediated interactions.
7. The cardiovascular benefit of statin therapy substantially exceeds its diabetes risk. The excess in new diagnoses is modest, dose-dependent, concentrated in people already near the diagnostic threshold, and reflects a glycemic shift of roughly 0.06–0.08% in HbA1c. Any adverse cardiovascular consequence of that shift is already fully captured within the net benefit observed in the same trials. Glycemic monitoring is the appropriate response; withholding statins is not.
8. Most intolerant patients who are willing to try again can be re-treated. Half of SAMSON participants and two-thirds of StatinWISE completers resumed statin therapy after seeing their own symptom data. Both figures come from patients who volunteered for rechallenge, and neither should be generalized to all patients who have discontinued a statin.

12. Limitations

• This is a narrative review, not a systematic review or a de novo meta-analysis. Studies were selected for relevance rather than by a prespecified search protocol, and no pooled estimates were independently calculated.
• Nocebo trials have a structural limitation that critics have fairly raised. SAMSON and StatinWISE recruited patients willing to undertake a rechallenge, which may under-represent the most severely affected. Blinded trials with run-in periods may also exclude susceptible patients before randomisationLa randomisation est le processus qui consiste à assigner les participants à un essai à des groupes de traitement ou témoins par le hasard, garantissant ainsi que les facteurs de confusion connus et inconnus sont répartis de manière égale ; lorsque la randomisation échoue — comme l'ont constaté des auditeurs dans le cas de PREDIMED —, les groupes peuvent différer d'une manière qui fausse l'effet apparent du traitement.. The nocebo literature should therefore be read as establishing that most reported symptoms are not drug-caused, not as establishing that pharmacological intolerance is rare in every individual.
• Efficacy percentages are drawn from trials with differing baselines, background therapy, and populations, and are not directly comparable across rows of Table 3.
• No reliable incidence estimate exists for statin-induced autoimmune hepatitis; the evidence base is case reports and pharmacovigilance disproportionality signals, which reflect reporting behavior rather than true frequency.
• Incidence estimates for anti-HMGCR IMNM vary by an order of magnitude depending on whether the denominator is the general population or the statin-exposed population, and case ascertainment depends on local availability of anti-HMGCR serology; the figures given in Section 5.2 should be read with that caveat.
• Investigational agent data derive partly from conference presentations and sponsor communications rather than peer-reviewed publication, and regulatory and trial status changes rapidly. Regulatory and guideline status in this review is current to 9 August 2026 and should be re-verified before publication.
• Absolute risk figures for statin-associated diabetes are sensitive to how intensively glycemia was ascertained in the contributing trials; relative estimates are the more transportable quantity, and the absolute rows of Table 9 should be read accordingly.
• The CoQ10 literature is genuinely unresolved on the question of symptomatic benefit from supplementation, and this review does not adjudicate it. The narrower question of whether muscle CoQ10 is depleted at all has clearer direct evidence and is treated accordingly.
• Fatigue and energy endpoints have not been examined in n-of-1 or blinded-versus-unblinded designs, so the proportion of statin-associated fatigue attributable to nocebo has not been quantified. The fatigue evidence and the nocebo evidence therefore rest on non-overlapping study designs and cannot be directly reconciled.

Références

1. World Health Organization. Global Health Estimates 2021: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2021. Geneva: World Health Organization; 2024. Accessed 8 August 2026.
2. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(10059):2532-2561. Published online 8 September 2016.
3. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement. Eur Heart J. 2015;36(17):1012-1022.
4. Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient. J Clin Lipidol. 2022;16(4):361-375.
5. Wood FA, Howard JP, Finegold JA, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. N Engl J Med. 2020;383(22):2182-2184. Published 15 November 2020.
6. Howard JP, Wood FA, Finegold JA, et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment (SAMSON). J Am Coll Cardiol. 2021;78(12):1210-1222. Published 13 September 2021.
7. Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016;375(22):2144-2153.
8. Lotta LA, Sharp SJ, Burgess S, et al. Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis. JAMA. 2016;316(13):1383-1391.
9. Nicholls SJ, Puri R, Anderson T, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373-2384.
10. Tsujita K, Sugiyama S, Sumida H, et al. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression (PRECISE-IVUS). J Am Coll Cardiol. 2015;66(5):495-507.
11. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87(19):2624-2757. doi:10.1016/j.jacc.2025.11.016. PMID 41824590.
12. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.
13. Raal FJ, Rosenson RS, Reeskamp LF, et al. Evinacumab for Homozygous Familial Hypercholesterolemia (ELIPSE HoFH). N Engl J Med. 2020;383(8):711-720. Published 20 August 2020.
14. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117-125. PMID 15660968.
15. Lipitor (atorvastatin calcium) tablets. Full prescribing information. Silver Spring (MD): US Food and Drug Administration; Drugs@FDA label repository. Label revision as posted at access. Accessed 8 August 2026.
16. Crestor (rosuvastatin calcium) tablets. Full prescribing information. Silver Spring (MD): US Food and Drug Administration; Drugs@FDA label repository. Label revision as posted at access. Accessed 8 August 2026.
17. Zocor (simvastatin) tablets. Full prescribing information. Silver Spring (MD): US Food and Drug Administration; Drugs@FDA label repository. Label revision as posted at access. Accessed 8 August 2026.
18. Pravachol (pravastatin sodium) tablets. Full prescribing information. Silver Spring (MD): US Food and Drug Administration; Drugs@FDA label repository. Label revision as posted at access. Accessed 8 August 2026.
19. Altoprev / Mevacor (lovastatin) tablets. Full prescribing information. Silver Spring (MD): US Food and Drug Administration; Drugs@FDA label repository. Label revision as posted at access. Accessed 8 August 2026.
20. Lescol XL (fluvastatin sodium) tablets. Full prescribing information. Silver Spring (MD): US Food and Drug Administration; Drugs@FDA label repository. Label revision as posted at access. Accessed 8 August 2026.
21. Livalo (pitavastatin) tablets. Full prescribing information. Silver Spring (MD): US Food and Drug Administration; Drugs@FDA label repository. Label revision as posted at access. Accessed 8 August 2026.
22. Cooper-DeHoff RM, Niemi M, Ramsey LB, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 Genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021. doi:10.1002/cpt.2557.
23. Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004;292(21):2585-2590.
24. Pinkosky SL, Newton RS, Day EA, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nat Commun. 2016;7:13457. Published 28 November 2016.
25. Cicero AFG, Fogacci F, Hernandez AV, et al. Efficacy and safety of bempedoic acid: pooled analysis of the CLEAR program. Curr Atheroscler Rep. 2022;24:791-801. Published 28 July 2022.
26. Ballantyne CM, Bays H, Catapano AL, et al. Role of Bempedoic Acid in Clinical Practice: pooled CLEAR Harmony and CLEAR Wisdom safety analyses. Cardiovasc Drugs Ther. 2021;35(4):853-864.
27. Zetia (ezetimibe) tablets. Full prescribing information. Silver Spring (MD): US Food and Drug Administration; Drugs@FDA label repository. Label revision as posted at access. Accessed 8 August 2026.
28. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (IMPROVE-IT). N Engl J Med. 2015;372(25):2387-2397.
29. Repatha (evolocumab) injection. Full prescribing information. Silver Spring (MD): US Food and Drug Administration; Drugs@FDA label repository. Label revision as posted at access. Accessed 8 August 2026.
30. Praluent (alirocumab) injection. Full prescribing information. Silver Spring (MD): US Food and Drug Administration; Drugs@FDA label repository. Label revision as posted at access. Accessed 8 August 2026.
31. Leqvio (inclisiran) injection. Full prescribing information. Silver Spring (MD): US Food and Drug Administration; Drugs@FDA label repository. Label revision as posted at access. Accessed 8 August 2026.
32. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). N Engl J Med. 2017;376(18):1713-1722.
33. Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (ODYSSEY OUTCOMES). N Engl J Med. 2018;379(22):2097-2107.
34. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (ORION-10 and ORION-11). N Engl J Med. 2020;382(16):1507-1519. Published 16 April 2020.
35. Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia (ORION-9). N Engl J Med. 2020;382(16):1520-1530.
36. US Food and Drug Administration. FDA approves first oral PCSK9 inhibitor to lower LDL cholesterol in adults with high cholesterol (enlicitide; Lipfendra). FDA news release, 16 July 2026. Accessed 8 August 2026.
37. Evkeeza (evinacumab-dgnb) injection. Full prescribing information. Silver Spring (MD): US Food and Drug Administration; Drugs@FDA label repository. Label revision as posted at access. Accessed 8 August 2026.
38. Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk (BROADWAY). N Engl J Med. 2025;393(1):51-61. doi:10.1056/NEJMoa2415820.
39. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (JUPITER). N Engl J Med. 2008;359(21):2195-2207. doi:10.1056/NEJMoa0807646.
40. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR Outcomes). N Engl J Med. 2023;388(15):1353-1364. Published 4 March 2023.
41. Nexletol / Nexlizet (bempedoic acid; bempedoic acid and ezetimibe) tablets. Full prescribing information. Silver Spring (MD): US Food and Drug Administration; Drugs@FDA label repository. Label revision as posted at access. Accessed 8 August 2026.
42. Nissen SE, Stroes E, Dent-Acosta RE, et al. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA. 2016;315(15):1580-1590. Published online 3 April 2016.
43. Raal FJ, Rosenson RS, Reeskamp LF, et al. The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia. JACC Adv. 2023;2(9):100648. doi:10.1016/j.jacadv.2023.100648. PMCID PMC11198175.
44. Navar AM, Mikhailova E, Catapano AL, Banka P, Blom DJ, Cadena A, Kourpanidis S, Lepor NE, Tsukamoto K, Mendizabal G, Nunez J, Zhang W, Zhu P, Zhuo M, Ballantyne CM; CORALreef Lipids Investigators. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med. 2026;394(6):529-539. doi:10.1056/NEJMoa2511002. PMID 41879224.
45. Ballantyne CM, Gellis L, Tardif JC, Banka P, Navar AM, Asprusten EA, Scott R, Stroes ESG, Froman S, Mendizabal G, Wang F, Catapano AL. Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. JAMA. 2026;335(2):129-139. doi:10.1001/jama.2025.20620. PMID 41206969.
46. gov. Enlicitide Decanoate (MK-0616) Cardiovascular Outcomes Study (CORALreef Outcomes). NCT06008756. Status: active, not recruiting; estimated primary completion 2029. Accessed 8 August 2026.
47. Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of Two Intensive Statin Regimens on Progression of Coronary Disease (SATURN). N Engl J Med. 2011;365(22):2078-2087. doi:10.1056/NEJMoa1110874.
48. Johnson TE, Zhang X, Bleicher KB, Dysart G, Loughlin AF, Schaefer WH, Umbenhauer DR. Statins induce apoptosis in rat and human myotube cultures by inhibiting protein geranylgeranylation but not ubiquinone. Toxicol Appl Pharmacol. 2004;200(3):237-250. doi:10.1016/j.taap.2004.04.010. PMID 15504460.
49. Jaśkiewicz A, Pająk B, Litwiniuk A, Urbańska K, Orzechowski A. Geranylgeraniol Prevents Statin-Dependent Myotoxicity in C2C12 Muscle Cells through RAP1 GTPase Prenylation and Cytoprotective Autophagy. Oxid Med Cell Longev. 2018;2018:6463807. doi:10.1155/2018/6463807.
50. Epelde F. Statin-Associated Muscle Symptoms and Myotoxicity: A Clinically Oriented Narrative Review with a Practical Prevention, Evaluation, and Management Algorithm. Medicina (Kaunas). 2026;62(6):1134.
51. Qu H, Guo M, Chai H, et al. Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2018;7(19):e009835.
52. Banach M, Serban C, Sahebkar A, et al. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc. 2015;90(1):24-34.
53. Dohlmann TL, Morville T, Kuhlman AB, et al. Statin Treatment Decreases Mitochondrial Respiration But Muscle Coenzyme Q10 Levels Are Unaltered: The LIFESTAT Study. J Clin Endocrinol Metab. 2019;104(7):2501-2508. doi:10.1210/jc.2018-01185.
54. Kuhlman AB, Morville T, Dohlmann TL, et al. Coenzyme Q10 Supplementation in Statin Treated Patients: A Double-Blinded Randomized Placebo-Controlled Trial. Antioxidants (Basel). 2022;11(9):1698. Published 29 August 2022.
55. Mikus CR, Boyle LJ, Borengasser SJ, et al. Simvastatin impairs exercise training adaptations. J Am Coll Cardiol. 2013;62(8):709-714. doi:10.1016/j.jacc.2013.02.074.
56. Ryan TE, Torres MJ, Lin C-T, et al. High-dose atorvastatin therapy progressively decreases skeletal muscle mitochondrial respiratory capacity in humans. JCI Insight. 2024;9(4):e174125. doi:10.1172/jci.insight.174125.
57. Morales-Palomo F, Ramirez-Jimenez M, Ortega JF, et al. Exercise Training Adaptations in Metabolic Syndrome Individuals on Chronic Statin Treatment. J Clin Endocrinol Metab. 2020;105(4):e1695-e1704.
58. Warden BA, Guyton JR, Kovacs AC, et al. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17(1):19-39. Published online 11 September 2022.
59. Wright RS, Koenig W, Landmesser U, et al. Safety and Efficacy of Inclisiran: Pooled and Extension Analyses of the ORION Program. J Am Coll Cardiol. 2021;77(9):1182-1193.
60. Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of Statins on Energy and Fatigue With Exertion: Results From a Randomized Controlled Trial. Arch Intern Med. 2012;172(15):1180-1182. Published online 11 June 2012. doi:10.1001/archinternmed.2012.2171.
61. Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of Statins on Skeletal Muscle Function (STOMP). Circulation. 2013;127(1):96-103. doi:10.1161/CIRCULATIONAHA.112.136101.
62. Ballard KD, Parker BA, Capizzi JA, et al. Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance. Atherosclerosis. 2013;230(1):121-124.
63. Mallinson JE, Marimuthu K, Murton A, et al. Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression. J Physiol. 2015;593(5):1239-1257.
64. Thompson PD, Parker B. Statins, exercise, and exercise training [editorial]. J Am Coll Cardiol. 2013;62(8):715-716.
65. Cholesterol Treatment Trialists’ Collaboration. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomized, double-blind trials. Lancet. 2022;400(10355):832-845. Published online 29 August 2022.
66. Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78(6):393-403. doi:10.3949/ccjm.78a.10073.
67. Khoo T, Tan E, Limaye V, Gunawardena H, Sadler R, Lamb JA, Lyu X, Brusch A, Needham M, Austin K, Bahadori A, Buch MH, Tomaszewski M, Lilleker JB, Chinoy H. The incidence of anti-HMGCR immune-mediated necrotizing myopathy: an Australian and UK retrospective multi-site cohort study. Rheumatology (Oxford). 2025;64(9):4995-5003. doi:10.1093/rheumatology/keaf238. PMID 40347460.
68. Mammen AL. Statin-Associated Autoimmune Myopathy. N Engl J Med. 2016;374(7):664-669.
69. Allenbach Y, Mammen AL, Benveniste O, Stenzel W. 224th ENMC International Workshop: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies. Neuromuscul Disord. 2018;28(1):87-99.
70. Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-Mediated Necrotizing Myopathy. Curr Rheumatol Rep. 2018;20(4):21.
71. Lim J, Rietveld A, De Bleecker JL, et al. Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurol Neuroimmunol Neuroinflamm. 2019;6(1):e513.
72. Giugliano RP, Mach F, Zavitz K, et al. Cognitive Function in a Randomized Trial of Evolocumab (EBBINGHAUS). N Engl J Med. 2017;377(7):633-643.
73. Cholesterol Treatment Trialists’ Collaboration. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycemia in large-scale randomized blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024;12(5):306-319. Published online 27 March 2024.
74. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Statins (class overview). Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Continuously updated resource; version as posted at access. Accessed 8 August 2026.
75. Wang B, Huang S, Li S, et al. Hepatotoxicity of statins: a real-world study based on the US Food and Drug Administration Adverse Event Reporting System database. Front Pharmacol. 2024;15:1502791. doi:10.3389/fphar.2024.1502791. Published online 7 January 2025.
76. Serrano-Pérez NH, Rodríguez-Martínez JS, Feria-Agudelo SM, et al. Drug-induced autoimmune hepatitis due to atorvastatin: a complex clinical case and literature review. Gastroenterol Rep. 2026;14:goag022.
77. Irwin JC, Khalesi S, Fenning AS, Vella RK. The effect of lipophilicity and dose on the frequency of statin-associated muscle symptoms: A systematic review and meta-analysis. Pharmacol Res. 2018;128:264-273. PMID 28943224.
78. Hou Q, Chen Y, Zhang Y, Pang C. Comparative Muscle Tolerability of Different Types and Intensities of Statins: A Network Meta-Analysis of Double-Blind Randomized Controlled Trials. Cardiovasc Drugs Ther. 2024;38(3):459-469. doi:10.1007/s10557-022-07405-0. Epub 2022 Nov 29. PMID 36447018.
79. SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy—a genomewide study. N Engl J Med. 2008;359(8):789-799.
80. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomized trials. Lancet. 2015;385(9965):351-361.
81. Penson PE, Bruckert E, Marais D, et al. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms: an International Lipid Expert Panel position paper. J Cachexia Sarcopenia Muscle. 2022;13(3):1596-1622.
82. Herrett E, Williamson E, Brack K, et al. Statin treatment and muscle symptoms: series of randomized, placebo controlled n-of-1 trials (StatinWISE). BMJ. 2021;372:n135. Published 24 February 2021.
83. Gupta A, Thompson D, Whitehouse A, et al. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA). Lancet. 2017;389(10088):2473-2481. Published 2 May 2017.
84. Clinical Pharmacogenetics Implementation Consortium. SLCO1B1, ABCG2 and CYP2C9 allele definition, allele functionality and frequency tables. Online resource at cpicpgx.org, versioned separately from the 2022 guideline; allele function assignment version of October 2025. Accessed 8 August 2026.
85. Hlatky MA, Gonzalez PE, Manson JE, et al. Statin-Associated Muscle Symptoms Among New Statin Users Randomly Assigned to Vitamin D or Placebo. JAMA Cardiol. 2023;8(1):74-80. doi:10.1001/jamacardio.2022.4250. PMID 36416841.
86. Rosenson RS, Miller K, Bayliss M, et al. The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): revision for clinical use, content validation, and inter-rater reliability. Cardiovasc Drugs Ther. 2017;31(2):179-186.
87. European Medicines Agency. Evlarco (obicetrapib/ezetimibe): summary of opinion. Committee for Medicinal Products for Human Use positive opinion adopted 23 July 2026; European Commission decision pending. Available from the EMA medicines register. Accessed 8 August 2026.
88. European Medicines Agency. Ubeslo (obicetrapib): summary of opinion. Committee for Medicinal Products for Human Use positive opinion adopted 23 July 2026; European Commission decision pending. Accessed 8 August 2026.
89. O’Donoghue ML, Rosenson RS, Gencer B, et al. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease (OCEAN(a)-DOSE). N Engl J Med. 2022;387(20):1855-1864.
90. Nissen SE, Wolski K, Watts GF, et al. Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a). N Engl J Med. 2025;392(17):1673-1683. doi:10.1056/NEJMoa2415818. PMID 40162643.
91. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-S45.
92. US Food and Drug Administration, Center for Drug Evaluation and Research. Integrated review, NDA 211616 (bempedoic acid). Silver Spring (MD): FDA; 2020. Accessed 9 August 2026.
93. Brandts J, Müller-Wieland D. Debate: Lipid-lowering Therapies and Diabetes Development. Curr Atheroscler Rep. 2025;27(1):24. doi:10.1007/s11883-024-01270-y.

Note on this reference list. The 91 entries are carried over in full from the master manuscript, and the body text is now numerically keyed to them: every claim resting on an external source carries a bracketed citation, and all 91 entries are cited at least once. Numbering follows the master list unchanged, so any existing cross-references to it remain valid. Two corrections were made on transfer. The date in entry 36 was corrected from 17 to 16 July 2026, the date carried by both the FDA press announcement and the Merck release. Entries 87 and 88 were verified against the EMA record: the CHMP adopted positive opinions for Ubeslo and Evlarco on 23 July 2026, announced 24 July, with the European Commission decision pending.

Two conventions are worth stating for the copy editor. Citations are placed at the end of the sentence or clause whose claim they support, and a single citation covers the preceding claim rather than the whole paragraph. Where a claim rests on several sources, they appear as a set (for example [34,35,59] for the ORION program). Table captions carry the citations for figures given in their rows, so the tables themselves are not individually annotated.